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Osteoarthritis (OA) the most common degenerative joint disease, characterized by 
articular cartilage degradation, has no cure and molecular mechanisms which cause the disease 
remain largely unknown. Although fibroblast growth factor 2 (FGF2) has been implicated in OA 
pathogenesis, previous findings showed contrasting roles and never examined if/how the varying 
isoforms (high molecular weight, HMW, or low molecular weight, LMW), in which the FGF2 
gene encodes, contribute to the disease. Clearly, there is a need to further understand the 
involvement of FGF2 isoforms in OA pathophysiology, which is the purpose of this research 
study.  
Using novel mouse models in which HMW or LMW FGF2 isoforms have been ablated 
(Fgf2
HMWKO
 and Fgf2
LMWKO
 mice) or overexpressed (HMWTg or LMWTg mice) we explored the 
role the isoforms play in OA. HMWTg mice phenocopy most traits in humans with X-linked 
hypophosphatemic rickets (XLH) and its murine homologue, the Hyp mouse, including 
increased FGF23 levels. Subjects with XLH and Hyp mice develop osteoarthropathy, and Hyp 
mice overexpress HMW FGF2 isoforms, which co-localized with FGF23 in HMWTg mice. 
There is crosstalk between FGF23 and Wnt/β-catenin signaling, both catabolic regulators in OA, 
and both upregulated in Hyp mice. Thus, we hypothesized that mice overexpressing HMW FGF2 
isoforms will develop OA, due to increased FGF23 that is propating the canonical Wnt signaling 
cascade.  Mice only expressing HMW FGF2 isoform (Fgf2
LMWKO
 mice) will develop OA, unlike 
mice only expressing LMW FGF2 (Fgf2
HMWKO
 mice).  
We assessed for signs of OA in these FGF2 isoform transgenic and knockout mice and 
found that HMWTg and Fgf2
LMWKO
 mice had loss of articular cartilage, increased OA markers,  
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abnormal subchondral bone structures, and increased FGF23/FGFR1 expression as indicated by 
radiography/microCT, histology, and qPCR analyses. HMWTg chondrocytes had increased 
expression of canonical Wnt signaling components, FGF23, and OA markers which were 
rescued after inhibition of Wnt as indicated by histology, qPCR, and Western blot analyses. OA 
was partially attenuated in HMWTg mice after neutralizing FGF23Ab treatment. 
Thus, HMW FGF2 modulates FGF23/FGFR1/Wnt/β-catenin signaling-mediated OA in 
chondrocytes, offering new insight into FGF2 and OA pathogenesis and a potential pathway to 
target in the future treatment of the disease. 
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Chapter 1 
Introduction 
1.1 Osteoarthritis 
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of 
chronic disability worldwide, as it affects over 27 million adults in the United States alone (1). 
OA is primarily present in the knee and was long thought to be caused by the wearing away of 
the articular cartilage surface, however the Osteoarthritis Research Society International 
(OARSI) has recently redefined the disease as a disorder of the entire joint to include not only 
degradation of cartilage, but abnormal remodeling of the subchondral bone and inflammation of 
the meniscus/synovium due to overall abnormal joint tissue metabolism (1,2). Specifically, 
hallmarks of OA include bone spur or osteophyte formation (3), dynamic alterations of 
trabecular architecture of the subchondral bone characterized by the thinning of underlying bone 
in early stages of OA disease due to increased bone resorption with subsequent sclerosis of bone 
in later stages (4), and vascular invasion/angiogenesis in the typically avascular cartilage tissue 
(5). In addition to loss of articular cartilage, there is a shift in the normally quiescent 
chondrocytes in which homeostasis is unable to be maintained, and the excessive catabolic 
activity results in increased production of degradative enzymes, a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS) and matrix metalloproteinases 
(MMPs),  and chondrocyte dedifferentiation and hypertrophy (6-9).  
The complexity of OA is only further enhanced due to the plethora of genetic and 
acquired factors, such as age and obesity, and biochemical and biophysical factors, such as 
proinflammatory cytokines and injury/instability, which contribute to the pathophysiology of the 
disease. This pathogenesis of OA activates various biochemical pathways, often in chondrocytes, 
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leading to an imbalance of anabolic and catabolic factors (6). The signaling pathways implicated 
in OA pathogeny are abundant and the molecular mechanisms underlying the disease are not 
fully understood. Thus, there is a critical need for additional studies to elucidate such 
mechanisms in order to develop therapeutic targets for the treatment of OA, as there are no 
current effective treatment options beyond total joint replacement (10). 
 
1.2 Mouse Models Used to Study OA 
 Although there are no disease modifying drugs to prevent or treat OA, there have been 
numerous animal studies dedicated to further understanding its initiation, development, and 
potential inhibition in an effort to find a treatment. As mentioned above, there are many 
molecular pathways involved in the maintenance of cartilage homeostasis and 
experimental/genetic modulation of these signaling pathways in murine models is used to study 
OA. Frequently, “knockout” (KO) mouse models are used in which the gene of interest has been 
systemically or tissue-specifically deleted and mice will spontaneously develop OA with age. 
For example, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), which is a necessary inhibitor of 
cartilage degradation by MMPs, when deleted in mice, results in changes similarly seen in 
humans with OA (11). Conversely, transgenic mouse models that overexpress the gene of 
interest can be used to study the involvement of various pathways in OA, such as mice that 
overexpress human MMP13 in articular chondrocytes which have severe joint destruction (7). 
Articular chondrocytes isolated from mice have been a useful way to study these pathways, too 
(12,13). In addition to spontaneous OA, post-traumatic OA can be induced in mice, using either 
control or genetically modified strains, through surgical procedures, such as destabilization of the 
medial meniscus (DMM) (14) or chemical manipulations, such as intra-articular injection of 
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collagenase, an enzyme that degrades the cartilage matrix (15). Recently, a more novel, 
noninvasive approach has been used in which mice undergo mechanical tibial compression 
loading (16). Despite these various models used to examine OA there still remains a need to 
identify catabolic players involved and continue to clarify the mechanism by which previously 
recognized signals contribute to the disease.  
  
1.3 FGF2, Focusing on its Role in OA 
 While numerous signaling factors participate in OA pathogenesis, the fibroblast growth 
factor (FGF) family, particularly FGF2, has received considerable attention in its regulation of 
cartilage and joint homeostasis (17,18). Though FGF2 is expressed by many different cell types 
and regulates cell growth, migration, differentiation, and survival during development, it is 
crucial for bone growth and cartilage metabolism (19) and is expressed by osteoblasts and 
chondrocytes (20). However, there is conflicting evidence supporting both the catabolic and 
anabolic potential of FGF2 within the joint. Specifically, exogenous FGF2 simulates MMP-13 
and ADAMTS-5 production in articular cartilage explants in vitro (17,21)
 
and the level of FGF2 
in OA synovial fluid is nearly twice that of healthy knees (18), suggesting catabolic functions. 
Also, FGF2 gene and protein expression was increased in human OA subchondral sclerotic 
osteoblasts (22). Alternatively, intra-articular injection of total FGF2 reversed OA progression in 
a surgically-induced OA mouse model (23) and Fgf2 knockout (Fgf2
ALLKO
) mice develop 
accelerated spontaneous and surgically-induced OA (24), signifying an anabolic role of FGF2. 
 These contradictory results may be due to the binding affinity of FGF2 for FGFR1 and 
FGFR3, which have contrasting roles in cartilage homeostasis. FGFR1 is elevated in human OA 
chondrocytes, promotes cartilage destruction (25), and its inhibition attenuates OA in murine 
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cartilage (26), while FGFR3 is reduced in human OA chondrocytes (25), drives anabolic activity 
in cartilage (27), and its deficiency accelerates murine OA (28). 
 
1.4 Isoforms of FGF2 in bone and its Mouse Models 
 Interestingly, FGF2 can be produced as distinct isoforms by alternative initiation of 
translation from a single mRNA, as it encodes for multiple protein isoforms including the high 
molecular weight (HMW) isoforms and the low molecular weight (LMW) isoform, which are 
ubiquitously expressed in cells, including osteoblasts. The LMW isoform is translated from the 
traditional AUG start codon, while the HMW isoforms are initiated upstream of the LMW start 
site from individual nonconventional CUG codons. Humans have three HMW FGF2 isoforms 
(22, 22.5, 24kDa), while rodents have two HMW FGF2 isoforms (21, 22kDa). The HMW FGF2 
isoforms contain a nuclear localization sequence, enabling the protein to function as an intracrine 
factor. Humans and rodents also have one LMW FGF2 isoform, which is transported out of the 
cell, acting as a conventional growth factor and functioning in an autocrine/paracrine fashion 
(29-31). It should be noted that there is evidence suggesting the capability of HMW FGF2 
having paracrine and/or autocrine activity, as it was shown to be exported from cardiac non-
myocytes (32).  
Mouse models in which the isoforms have been selectively deleted or overexpressed have 
been developed and studied, particularly in the context of skeletal biology, but never utilized to 
examine OA. Mice constitutively deficient in LMW FGF2, Fgf2
LMWKO
 mice, were previously 
created and characterized (33) and of importance, had decreased bone mineral density (BMD) 
compared to WT mice (34), a trait also observed in mice with a full-length deletion of FGF2 
(Fgf2
ALLKO
 mice) (35).  In a comparable manner mice lacking HMW FGF2, Fgf2
HMWKO
 mice 
were generated and characterized (36) and found to have increased BMD (37). Our lab generated 
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mice that overexpress LMW FGF2 in osteoblastic lineage cells, using a Col3.6 promoter, 
(LMWTg mice) and found an increase in bone mass and BMD (34). We similarly developed 
mice that overexpress HMW FGF2, using a Col3.6 promoter (HMWTg mice) which were found 
to have decreased BMD, dwarfism, rickets, osteomalacia, hypophosphatemia, and increased 
FGF23 in bone. These are all traits in which the HMWTg mice phenocopy humans with X-
linked hypophosphatemia (XLH) (38).  
 
1.5 XLH and FGF23 
 XLH is the most common form of inherited vitamin D-resistant rickets, affecting 1 in 
20,000 people, and leads to renal phosphate wasting, inappropriately high levels of circulating 
FGF23, growth retardation, osteomalacia, rickets, and osteoarthropathies (39). Joint pain is the 
most common symptom in adults, which can be attributed to the development of enthesopathy 
(mineralization of the tendon and ligament insertion sites)  and OA, hallmarks of XLH, and 
include thinning of articular cartilage and sclerosis of subchondral bone (40, 41). Just as our 
HMWTg mice phenocopy XLH, so does the Hyp mouse, the murine homologue to XLH, which 
has a deletion in the Phex gene and is known to develop the same characteristic traits of humans 
with XLH, including hypophosphatemia and elevated FGF23 levels (42). Also, enthesopathy and 
osteophyte formation were observed in Hyp mice (43). Other signs of degenerative joint disease 
were prominent in these mice including, decreased articular cartilage thickness, increased 
chondrocyte alkaline phosphatase activity, defective mineralization, and angiogenesis of the 
cartilage (44). While osteoarthropathy is present in both humans with XLH and Hyp mice, this 
was not previously examined in our HMWTg mice and the mechanism responsible for the 
observed joint degeneration was unknown.  
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 We have previously shown that the traits in which HMWTg mice phenocopy Hyp mice 
include dwarfism, decreased BMD, rickets, osteomalacia, hypophosphatemia, and increased 
levels of FGF23, in serum and bone. Also, Hyp mice overexpress FGF2 HMW isoforms. Also, 
we reported that HMW FGF2 modulates and co-localizes with FGF23 in HMWTg mice (38). 
There is a great deal of evidence implicating the destructive role FGF23 has in cartilage and joint 
homeostasis, as FGF23 has been found to be upregulated in human OA chondrocytes (45) and 
exogenous FGF23 expression stimulates hypertrophy and increases FGFR1 production in 
chondrocytes (46,47). Thus, increased HMW FGF2 may be responsible for elevated FGF23 
levels, which is causing the OA phenotype. 
 
1.6 Wnt Signaling, Focusing on its Role in OA 
 The Wnt/β-catenin signaling pathway regulates cell migration, differentiation, and 
proliferation and is essential for cartilage development and homeostasis (48,49). Wnt ligands, 
cysteine-rich glycoproteins, initiate downstream signaling by binding to either low-density 
lipoprotein-related receptor (LRP) 5 or 6 facilitating interaction with Axin2, a component of the 
multi-protein β-catenin destruction complex which includes glycogen synthase kinase (GSK) 3, 
allowing stabilization, accumulation, and translocation of β-catenin to the nucleus where it 
complexes with T cell factor/Lymphoid-Enhancing Factor (Tcf/Lef) to modulate transcription of 
various target genes (48). Although aberrant noncanonical Wnt signaling can impact cartilage 
(49,50), there is a wide variety of literature recognizing the tremendous importance of canonical 
Wnt/β-catenin signaling (51-58). Particularly, excessive canonical Wnt signaling has been shown 
to negatively impact cartilage, as observed by an upregulation in Wnt7b, Wnt16, LRP5, and 
nuclear β-catenin expression in OA cartilage (53-56). Mice deficient in LRP5 were protected 
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from experimental OA and LRP5 was determined to be responsible for Wnt-induced cartilage 
destruction by regulating production of MMPs (53). Also, it was found that increased Sclerostin 
(Sost) and Dickkopf WNT Signaling Pathway Inhibitor (Dkk1) levels (Wnt inhibitors) protect 
against cartilage degradation in OA in mice (57,58). 
 It has been well established that FGF23 stimulates hypertrophy due to signaling through 
FGFR1 (46,47), and FGFR signaling was found to increase Wnt/β-catenin signaling in 
chondrocytes (59). Also, FGF signaling can elevate nuclear -catenin levels through inactivating 
GSK3 (60), and Wnt/-catenin activity can stimulate FGF23 promoter activity in osteoblasts 
(63). Additionally, Wnt signaling components are enhanced in Hyp mice (61, 62), which have 
increased levels of FGF23 and develop osteoarthropathy (38,43,61). Together these studies 
imply that FGF23 and canonical Wnt signaling cooperatively may be contributing to OA. 
 
1.7 Specific Aims 
As previously discussed, OA is a complex and disabling joint disease, characterized 
mainly by articular cartilage degradation, and affects tens of millions of people (1), costing the 
US economy over $86 billion dollars a year (63). Beyond total joint replacement surgery there is 
no effective treatment option (10), so there is a critical need to elucidate the molecular 
mechanism responsible for OA in order to identify therapeutic targets to treat the disease, which 
is the purpose of this research project.  
Although many biochemical pathways are implicated in OA pathogenesis, FGF2 and FGF 
signaling are known to be important in cartilage homeostasis and degradation, with some studies 
recognizing FGF2 as catabolic and others regarding FGF2 is chondroprotective (17,18,21-23). 
These conflicting reports indicate that a more comprehensive analysis is required to further 
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understand its specific mechanism(s). Though the high molecular weight (HMW) and low 
molecular weight (LMW) isoforms in which the FGF2 gene encodes, have been studied in bone 
(37,34), their impact on joint and cartilage was never examined. We explore the role that the 
individual FGF2 isoforms play in OA using mouse models, in which either HMW or LMW 
FGF2 isoforms have been ablated (Fgf2
HMWKO
 and Fgf2
LMWKO
 mice) or overexpressed (HMWTg 
or LMWTg mice). Importantly, HMWTg mice phenocopy most traits in humans with XLH and 
its murine homologue, the Hyp mouse, including increased FGF23 in serum and bone (38,42). 
Subjects with XLH and Hyp mice also develop degenerative joint disease (39,43,44), and Hyp 
mice overexpress HMW FGF2 isoforms, which was found to co-localize with FGF23 in 
HMWTg mice (38). FGF23 negatively impacts cartilage via FGFR1 (46,47), and FGFR 
signaling was found to increase Wnt/β-catenin signaling in chondrocytes (59), a pathway known 
to contribute to OA (48,49), which is also upregulated in some tissues of the Hyp mouse (61,62). 
Again, HMWTg mice phenocopy subjects with XLH and Hyp mice (known to have increased 
HMW FGF2 associated with enhanced FGF23 expression and activated canonical Wnt 
signaling). 
 Since both XLH subjects and Hyp mice develop OA, the central hypotheses are: i) Mice 
overexpressing HMW FGF2 isoforms, in which FGF23 is increased, will develop more severe 
OA signs than Vector control mice. ii) Fgf2
LMWKO
 mice (which only express the HMW FGF2 
isoform) will be more likely to develop OA compared to the wild-type, whereas, the Fgf2
HMWKO
 
mice will not develop OA as frequently or severely as the wild-type. iii) The HMW FGF2 
isoforms cause upregulation of FGF23, which binds to FGFR1 propagating the canonical Wnt 
signaling cascade, promoting an OA phenotype. These hypotheses will be tested through the 
following aims: 
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Aim 1: Determine if overexpression of HMWFGF2 isoforms leads to severe OA.   
1A) Characterize the OA phenotype in HMWTg mice. 
1B) Characterize FGF and FGFR signaling in HMWTg knee joints. 
Rationale/hypothesis: Since HMWTg mice phenocopy subjects with XLH and Hyp mice, which 
are shown to develop OA, the hypothesis is that HMWTg mice will develop more severe signs of 
OA compared to the Vector control. Also, FGF2, FGF23, FGFR1, and FGFR3 expression is 
known to be modulated in OA, therefore we posit that HMWTg mice will have altered 
expression levels within the joint, particularly an increase in FGF23.  
In order to assess for signs of degenerative joint disease in HMWTg and Vector mice 
radiographic imaging, microCT analysis, histological methods (immunohistochemistry, Safranin-
O/von Kossa/alkaline phosphatase staining) and qPCR analysis of RNA extracted from whole 
knee joints will be used. These methods will identify any abnormalities in the subchondral bone, 
loss of proteoglycan content and articular cartilage integrity, and increases in matrix 
metalloproteinases/genes implicated in OA (degradative enzymes such as MMP13, Adamts5, 
etc.), in knees of 2, 8, and 18-month-old HMWTg and Vector control mice and also compared to 
LMWTg mice. Immunohistochemistry and qPCR analysis will be used to examine FGF and 
FGFR expression. 
 
Aim 2: Examine the role of selective deletion of HMWFGF2 isoforms and LMWFGF2 
isoform in the development of OA.  
Rationale/hypothesis: Since deletion of total FGF2 causes OA in mice, we want to examine 
whether selectively deleting either the LMW or HMW isoform of FGF2 will cause an OA 
phenotype. The hypothesis is that Fgf2
LMWKO
 mice that only express the HMW FGF2 isoforms 
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(which are increased in Hyp mice that develop OA), will be more likely to develop OA 
compared to the wild-type, similar to that observed in Fgf2
ALLKO
, whereas, the Fgf2
HMWKO
 mice 
will not develop OA as frequently or severely as their wild-type littermate control, as these mice 
do not possess the HMW FGF2 isoforms.   
In order to assess for signs of spontaneous OA the techniques proposed in Aim 1 will be 
employed for knee joints from 2, 6, and 9-month-old male Fgf2
ALLKO
, Fgf2
HMWKO
, and 
Fgf2
LMWKO
, and their WT littermates. We will also use another OA model, involving tibial 
compression loading, in order to determine if it further accelerates OA in mice or if mice are 
protected from OA induction.   . 
 
Aim 3: Determine if HMW FGF2 isoform contributes to OA via modulation of  
FGF23/FGFR1 and canonical Wnt signaling cascade.  
Rationale/hypothesis: Given the crosstalk and involvement in cartilage degradation between 
FGF23-Wnt/β-catenin signaling and the upregulation of both FGF23 and active β-catenin in Hyp 
mice, which also overexpress HMW FGF2 and develop OA, we will determine if HMWTg 
cartilage has increased Wnt components resulting in OA. The hypothesis is that OA may be 
caused by the overabundance of FGF23, which binds to FGFR1, activating canonical Wnt/β-
catenin signaling leading to an increase in degradative enzymes/hypertrophy.  
In vivo studies-In order to determine if components of the Wnt signaling pathway are 
increased in HMWTg knees compared to Vector, qPCR analysis will be used following RNA 
extraction from whole joints and immunohistochemistry used to examine protein expression and 
location. Also, HMWTg (and Vector) mice will be treated with an FGF23 neutralizing antibody 
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in vivo to determine if blocking of FGF23 inhibits FGFR1 signaling/OA marker gene expression, 
and if the OA phenotype is attenuated in HMWTg mice. 
In vitro studies- In order to determine if FGF23-Wnt signaling and OA marker 
expression is enhanced in HMWTg chondrocytes, primary chondrocytes will be harvested and 
cultured from HMWTg mice and compared to those from Vector and LMWTg mice.  
Gene/protein expression of Wnt signaling components/OA markers will be examined by qPCR 
and Western blot analyses. Alcian blue and alkaline phosphatase staining will be used to 
determine if HMWTg chondrocytes appear to be more hypertrophic/osteoarthritic. In order to 
characterize the molecular mechanism, cultures will be treated with a potent canonical Wnt 
inhibitor to determine if the factors downstream of the inhibitor are decreased and OA marker 
expression is reduced. 
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2.1 Abstract  
Humans with X-linked hypophosphatemia (XLH) and Hyp mice, the murine homologue 
of the disease, develop severe osteoarthropathy and the precise factors that contribute to this joint 
degeneration remain largely unknown.  Fibroblast growth factor 2 (FGF2) is a key regulatory 
growth factor in osteoarthritis. Although there are multiple FGF2 isoforms the potential 
involvement of specific FGF2 isoforms in joint degradation has not been investigated. Mice that 
overexpress the high molecular weight FGF2 isoforms in bone (HMWTg mice) phenocopy Hyp 
mice and XLH subjects and Hyp mice overexpress the HMWFGF2 isoforms in osteoblasts and 
osteocytes. Since Hyp mice and XLH subjects develop osteoarthropathies we examined whether 
HMWTg mice also develop knee joint degeneration at 2, 8, and 18-month-old compared with 
VectorTg (control) mice. HMWTg mice developed spontaneous osteoarthropathy as early as 2 
months of age with thinning of subchondral bone, osteophyte formation, decreased articular 
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cartilage thickness, abnormal mineralization within the joint, increased cartilage degradative 
enzymes, hypertrophic markers, and angiogenesis. FGF receptors 1 and 3 and fibroblast growth 
factor 23 were significantly altered compared to VectorTg mice. In addition, gene expression of 
growth factors and cytokines including bone morphogenetic proteins, Insulin like growth factor 
1, Interleukin 1 beta, as well transcription factors Sex determining region Y box 9, hypoxia 
inducible factor 1 and nuclear factor kappa B subunit 1 were differentially modulated in 
HMWTg compared with VectorTg. This study demonstrates that overexpression of the HMW 
isoforms of FGF2 in bone results in catabolic activity in joint cartilage and bone that leads to 
osteoarthropathy.   
2.2 Introduction 
X-linked hypophosphatemia (XLH), the most common form of inherited vitamin D-resistant 
rickets, which affects 1 in 20,000 people, leads to renal phosphate wasting, inappropriately high 
levels of circulating fibroblast growth factor 23 (FGF23), rickets, growth retardation, 
osteomalacia, and osteoarthropathies (39). The most common symptom in adults is joint pain, 
which can be attributed to the development of enthesopathy and osteoarthritis, both hallmarks of 
XLH, which include thinning of articular cartilage and sclerosis of subchondral bone (40, 41). 
The Hyp mouse, a murine homologue of XLH is known to develop the same signs of humans 
with XLH, including hypophosphatemia and elevated levels of FGF23 (42). More recently, the 
Hyp mouse was found to develop enthesopathy, which included mineralization of the tendon and 
ligament insertion sites, as well as, osteophyte formation (43). Degenerative osteoarthropathy 
was also prominent in these mice, which was characterized by decreased articular cartilage 
thickness, increased chondrocyte alkaline phosphatase activity, defective mineralization, and 
vascular invasion of the cartilage (44). 
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We have previously developed transgenic mice that phenocopy the Hyp mouse and 
subjects with XLH, by overexpressing the high molecular weight isoforms (HMW) of fibroblast 
growth factor 2 (FGF2) under a Col3.6 promoter (HMWTg mice) (38). The FGF2 gene encodes 
multiple protein isoforms with varying molecular weights. Humans have three HMW FGF2 
isoforms (22, 22.5, 24kDa), and rodents have two HMW FGF2 isoforms (21, 22kDa).  These 
HMW FGF2 isoforms possess a nuclear localization sequence that enables the proteins to 
function in an intracrine manner. Humans and rodents also have one low molecular weight 
(LMW) FGF2 isoform that is exported from cells which functions in an autocrine and/or 
paracrine manner (30, 31). The bone phenotype of HMWTg mice was previously fully 
characterized and it was also determined that HMWTg mice develop dwarfism, decreased bone 
mineral density, rickets, osteomalacia, and hypophosphatemia, and display increased FGF23, in 
serum and bone, which are the traits in which the HMWTg mice phenocopy Hyp mice (38). 
Also, Hyp mice were previously reported to overexpress the HMW FGF2 isoforms (38). Since 
the Hyp mouse, as well as, humans with XLH develop osteoarthropathies (40, 44)
 
the aim of our 
study was to determine if HMWTg mice also develop joint degeneration. 
This study is of particular importance since recently FGF2 has received considerable 
attention in the regulation of cartilage and joint homeostasis (18, 24). There is conflicting 
evidence that demonstrates both catabolic and anabolic potential of FGF2 in the joint 
(17,18,21,24) and no studies, as of yet, addressed the specific FGF2 isoforms in the development 
of osteoarthropathy.  
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2.3 Materials and Methods  
 
2.3.1. Experimental Animals 
All animal protocols were approved by the UConn Health Institute of Animal Care and Use 
Committee. We have previously described in detail the generation of HMWTg and 
control/vector transgenic mice (VectorTg) (38). Briefly, the Col3.6-HMW-IRES-green 
fluorescent protein-sapphire (GFPsaph) construct was created by inserting HMW isoforms of 
human Fgf2 (22, 23, and 24 kDa) cDNA in previously made Col3.6-CAT-IRES-GFPsaph in 
place of a chloramphenicol acetyltransferase fragment. This expression construct is able to 
concurrently overexpress HMW and GFPsaph from a single bicistronic mRNA. The Col3.6-
IRES/GFPsaph (Vector), which overexpresses the transgene cassette without the additional 
FGF2 coding sequences, was created as a control. Col3.6-CAT-IRES-GFPsaph or Col3.6-
IRES/GFPsaph construct inserts were released via digestion by AseI and AflII. The Gene 
Targeting and Transgenic Facility at UCONN Health performed microinjections in the pronuclei 
of fertilized oocytes. The individual transgenic mouse lines were established by breeding founder 
mice of the F2 generation of the FVBN strain with wild-type mice. Male homozygous VectorTg 
and HMWTg mice at 2 (n=10-11/group), 8 (n=7-8/group), and 18 (n=4-7/group) months of age 
were used in this study. We utilized two independent lines of HMWTg mice, Line 203 (for 2 and 
8-month-old mice) and Line 204 (for 18-month-old mice), which were previously extensively 
characterized (38). Male homozygous mice that overexpress the human low molecular weight, 
18-kDa isoform, of FGF2 (LMWTg mice) were created in a similar manner as described above 
(34)
 
and were compared to the VectorTg controls at 19 months of age (n=4/group) for 
development of osteoarthropathy.  
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2.3.2. Radiology and Micro-computed tomography  
Digital radiographs of murine knee joints were obtained with a SYSTEM MX 20 from Faxitron 
X-ray Corporation. Imaging of left knee architecture was performed using ex vivo micro-
computed tomography (μCT40, ScanCo Medical AG, Bassersdorf, Switzerland). The region of 
subchondral trabecular bone of the epiphysis in the femur and tibia were analyzed by 3-
dimensional μCT for the following morphometric parameters: bone volume/tissue volume 
(BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular number 
(Tb.N). 
 
2.3.3. Histology 
Whole knee joints were dissected and fixed in 4% paraformaldehyde for 6 days followed by 
decalcification with 14% EDTA solution. Specimens were processed for paraffin embedding in a 
frontal orientation and 7-μm alternate sections were obtained. After sections were de-
paraffinized and rehydrated, Safranin-O staining of glycosaminoglycans was performed using 
0.1% aqueous Safranin-O, followed by counter-staining using Weigert’s Iron Hematoxylin and 
0.02% aqueous Fast Green. For alkaline phosphatase and von Kossa staining, the knees were 
formalin fixed, cryomatrix (Thermo Electron Corp., Pittsburgh, PA) embedded, and sectioned at 
6-μm. Alkaline phosphatase staining was done by incubating tissue with 100mM Tris-HCl buffer 
(pH 8.2) for 10 minutes, followed by incubation with Vector Blue Alkaline Phosphatase 
Substrate (Vector Laboratories, Burlingame, CA, USA) for 30 minutes.  
 
2.3.4. Immunohistochemistry and RNAscope 
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Immunohistochemical staining was performed using ImmunoCruz™ ABC Staining System 
(Santa Cruz Biotechnology, CA, USA) and DAB Peroxidase Substrate kit (Vector Laboratories, 
Burlingame, CA, USA). Following de-paraffinization and rehydration, sections were incubated 
at 95°C with 10mM sodium citrate buffer for 10 minutes for antigen retrieval. Once cooled to 
room temperature for 30 minutes, 3% hydrogen peroxide in water was added to the sections for 
15 minutes. After blocking with 10% serum for one hour, the slides were incubated with primary 
antibodies in blocking buffer overnight at 4°C. Details of the following primary antibodies are in 
Table 1: rabbit anti-MMP13 (Abcam), rabbit anti-ADAMTS5 (Abcam), rabbit anti-FGF-2 (Santa 
Cruz), rabbit anti-FGFR-1 (Santa Cruz), rabbit anti-FGFR-3 (Santa Cruz), rabbit anti-VEGF 
(Santa Cruz),  anti-FGF-23 (R & D Systems, MN, USA), rabbit anti-NF-kB p65 (Abcam), and 
anti-rabbit SOX9 (Abcam). Slides were then washed with TBS containing 0.1% Tween 20 and 
incubated with the appropriate 1:200 biotinylated secondary antibody at room temperature for 30 
minutes. Next, slides were washed and developed with DAB substrate solution, followed by 
counterstaining with Harris hematoxylin. RNAscope was performed using Formalin-Fixed 
Paraffin-Embedded Sample Preparation and Pretreatment, RNAscope® 2.5 HD Detection 
Reagent, and the probe for mouse Col10a1 according to the manufacturer’s instructions 
(Advanced Cell Diagnostics, Newark, CA).  
 
2.3.5. RNA isolation and real time PCR 
Following skin and bulk muscle removal from 2-month-old VectorTg and HMWTg mice, total 
RNA was extracted from whole joints including all structures of the joint, above the growth 
plate, using TRIzol reagent (34). RNA was reverse-transcribed to cDNA using RNA to cDNA 
EcoDry Premix kit (Clontech Inc., A Takara Bio Company). For real time quantitative reverse 
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transcription-PCR (qPCR) analysis a Bio-Rad MyiQ system was used with iTaq
TM
 Universal 
SYBR Green Supermix (Bio-Rad, CA, USA). The primers used for real-time PCR (Table 2) 
were synthesized by IDT (Integrated DNA Technologies, Inc., CA). The relative change in 
mRNA was normalized to the housekeeping gene Beta-actin (β-actin) which served as an 
internal reference for each sample. For each group the mRNA level is expressed as the fold 
change relative to the first sample.   
 
2.3.6. Determination of articular cartilage thickness 
Articular cartilage thickness was determined based on a method previously reported (64) by 
using Safranin-O stained sections and measuring the mean distance at the thickest point from the 
articular cartilage surface to the subchondral bone interface across three points per section using 
ImageJ. Images were taken at 20x from three separate representative sections from each knee, 
closest to the center of the joint, from different VectorTg and HMWTg mice (n=3-4/group). 
 
2.3.7. Statistical analysis 
Results are presented as means ± S.D. Student’s t-test was used to analyze differences between 
groups. Differences were considered significant at p values less than 0.05, unless otherwise 
stated. 
 
2.4 Results 
2.4.1. Time course of radiological and morphometric changes in VectorTg and HMWTg knee 
joints 
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Digital radiographs were assessed for indications of OA in the bone of VectorTg and HMWTg at 
2, 8, and 18 months of age (Fig. 1A). All (11 out of 11) knee joints of HMWTg mice at 2 months 
of age showed flattening of the tibial plateau and thinning of femoral subchondral bone. 
Additionally, the knee joints of all (8 out of 8) HMWTg mice at 8 months old displayed thinning 
of subchondral bone, as well as, osteophyte formation mainly on the posterior tibiae. Joint 
destruction was apparent in 18-month-old HMWTg mice, characterized by osteophyte formation, 
sclerotic bone development, and narrowing of the patellofemoral space (7 out of 7). Conversely, 
radiographs of VectorTg mice did not display evidence of skeletal joint deterioration at any age. 
Micro-CT images of HMWTg knees showed thinning of the subchondral bone of the 
femur and tibia along with greater loss of trabeculae compared to VectorTg at 2 and 8 months of 
age (Fig. 1B). By 18 months of age, evidence of severe OA was noted in HMWTg knees, which 
included sclerosis of the femur. Also, three-dimensional (3D) surface renderings of HMWTg 
knees showed pitting, erosion, and deterioration, which increased in intensity with age, while the 
VectorTg subchondral plate retained smooth contour and joint integrity. 3D morphometric 
parameters calculated from micro-CT results of the epiphysis of HMWTg femurs and tibiae were 
significantly different from those of VectorTg mice at 2 and 8 months of age. Specifically, 
HMWTg epiphyses displayed modifications of the trabecular architecture that are indicative of 
early OA-like changes (Fig. 1C & D). At 2 months of age the bone volume/tissue volume 
(BV/TV) of the HMWTg epiphysis was decreased in both the femur and tibia by 35% (P <0.01) 
and 11% (P <0.01), respectively, compared to the VectorTg. The trabecular thickness (Tb.Th) of 
the HMWTg epiphysis was decreased in the femur and tibia at 2 months by 16% (P <0.001) and 
11% (P <0.01), respectively, compared to the VectorTg. Also, at 2 months the femur of HMWTg 
mice had an increase in trabecular spacing (Tb.Sp) by 16% (P <0.05) and a decrease in 
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trabecular number (Tb.N) by 17% (P <0.05) compared to VectorTg. Moreover, at 8 months of 
age, the epiphysis of the femur and tibia of HMWTg had a decrease in BV/TV by 42% (P <0.05) 
and 27% (P <0.05), respectively, compared to the VectorTg. The Tb.Sp was increased by 32% 
(P <0.05) and the Tb.N was decreased by 25% (P <0.05) in 8-month-old HMWTg femoral 
epiphyses, compared those of the VectorTg.  
 
2.4.2. Histological changes in VectorTg and HMWTg cartilage 
Articular cartilage integrity was determined histologically using Safranin-O staining to examine 
proteoglycan content in 2, 8, and 18-month-old mice. A dramatic decrease in Safranin–O 
staining (proteoglycan content) and articular cartilage thickness was found in HMWTg knees at 
all ages, particularly on the lateral side (Fig. 2A, circled area). Osteophytes, formed through 
endochondral ossification of cartilaginous tissue, were also present in 18-month-old HMWTg 
knees (Fig. 2B). The average tibial articular cartilage thickness was significantly decreased in 2-
month-old HMWTg knees compared to VectorTg by 56%, in 8-month-old HMWTg compared to 
VectorTg by 65%, and in 18 month HMWTg compared to VectorTg by 62%(Fig. 2C). 
We also examined GFP localization in the joints of 1-month-old HMWTg and VectorTg 
mice as a readout of transgene expression. GFP was expressed by osteocytes and osteoblasts in 
the bone areas of both strains, but was absent from the articular cartilage and tendons. Notably, 
GFP was markedly more intense in HMWTg tissues. These results confirmed bone-targeted 
overexpression of HMW FGF2 isoforms in the HMWTg mice (Fig. 3). 
Furthermore, in order to confirm that overexpression of the LMW FGF2 isoform does not 
lead to joint degeneration, we examined knees of 19-month-old VectorTg and LMWTg mice and 
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found that there was no phenotypic difference in the subchondral bone by x-ray imaging and 
similar articular cartilage thickness between both groups (Fig. 4).   
 
2.4.3. Expression of OA markers in VectorTg and HMWTg knees  
Total RNA was extracted from knee joints of 2-month-old VectorTg and HMWTg mice and used 
for measurement of mRNA of genes that are typically upregulated in OA articular cartilage, 
including MMP-13 (a collagenase) and type X collagen (hypertrophic chondrocyte marker). Both 
MMP-13 and type X collagen mRNA expression was significantly increased in HMWTg joints 
(Fig. 5A). Additionally, immunohistochemistry was utilized to determine the localization and 
expression of MMP-13 and ADAMTS-5 (the major aggrecan degrading enzyme in murine 
cartilage). In 2-month-old HMWTg joints, expression of MMP-13 and ADAMTS-5 was 
increased in all joint tissues but particularly in the articular cartilage, compared to VectorTg (Fig. 
5B & C). MMP-13 expression was also present in the enlarged tendon area of HMWTg knees, 
but was not present in VectorTg. MMP-13 expression in 8-month-old HMWTg joints was 
observed within the articular cartilage and in a developing osteophyte area (Fig. 5B) and 
ADAMTS-5 expression in the articular cartilage was also increased compared the VectorTg (Fig. 
5C). In 18-month-old HMWTg knees, MMP-13 expression was increased overall compared to 
the VectorTg, most notably in the enlarged tendon areas near the femur (Fig. 5B). Similarly, 
ADAMTS-5 expression was increased in these HMWTg knees compared to the VectorTg knees, 
particularly along the articular cartilage (Fig. 5C). Furthermore, RNAscope was utilized to 
examine Col X expression, which showed an increase in labeled articular chondrocytes in 
HMWTg knees compared to the very few cells which were labeled in the VectorTg at 2 months 
of age (Fig. 5D). 
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 Since HMWTg mice developed an OA phenotype and since multiple cytokines, growth 
factors and oxidative stress and their downstream signaling pathways have been involved in the 
regulation of OA like changes in the subchondral bone as well as hypertrophic-like changes in 
osteoarthritic articular chondrocytes (65, 66), we examined gene expression in whole joints from 
2-month-old Vector and HMWTg mice. We observed significant increases in the mRNA for 
bone morphogenetic protein 2 (Bmp2), bone morphogenetic protein 4 (Bmp4), insulin like 
growth factor 1(Igf1), interleukin 1 beta (Il-1β), and hypoxia inducible factor 1(Hif1α) compared 
to the VectorTg (Table 3). There was no increase in transforming growth factor beta (Tgfβ1 or 
Tgfβ3) or tumor necrosis factor alpha (Tnfα) or Indian hedgehog (Ihh), (data not shown). We 
also observed a significant increase in the transcription factors, Sex determining region Y box 9 
(Sox9), and nuclear factor kappa B subunit 1 (Nf-κb1) (Fig. 6A) in joints from HMWTg 
compared with Vector. Since Sox9 and NF-κB signaling is important in the response to multiple 
inducers of OA, we also examined P65 subunit of NF-κB by immunohistochemistry and found 
there was expression throughout the articular cartilage of 2-month-old HMWTg mice, but no 
expression in the VectorTg (Fig. 6B). Also, Sox9 expression was dramatically increased in the 
cartilage and menisci of HMWTg joints compared to VectorTg (Fig. 6C). 
 
2.4.4. Evaluation of characteristics of osteoarthopathies in VectorTg and HMWTg joints 
Although vascular endothelial growth factor (Vegf) mRNA levels were similar in both genotypes 
(data not shown), there was increased VEGF protein expression in 2-month-old HMWTg 
subchondral bone and articular cartilage (a typically avascular region) compared to VectorTg 
joints (Fig. 7A). Alkaline phosphatase staining was used to visualize the expression and 
localization of hypertrophic chondrocytes, which showed an increase in HMWTg joints, 
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encroaching upon a greater area of the articular surface compared to that of the VectorTg (Fig. 
7B). Mineral deposition was determined by von Kossa staining (Fig. 7C). VectorTg mice showed 
mineralization, which corresponded to the alkaline phosphatase stained area of the articular 
cartilage, whereas, the HMWTg mice showed less mineral deposition in areas that did contain 
alkaline phosphatase-positive chondrocytes. Also, there was evidence of mineralization on the 
meniscus in HMWTg mice (Fig. 7B & C).     
 
2.4.5. Expression of FGF Receptors and ligands in VectorTg and HMWTg knee joints 
Since HMWTg mice overexpress the HMW FGF2 isoforms, which results in increased FGF2 in 
bone (38) and also increased FGF23 expression in serum and bone (38), we examined total FGF2 
and FGF23 expression within the joint. Fgf2 mRNA expression was significantly increased in 2-
month-old HMWTg compared to the VectorTg (P <0 .01) and Fgf23 mRNA expression was 
increased but did not reach significance (Fig. 8A). Immunohistochemistry confirmed that FGF2 
protein expression was increased in the articular cartilage, meniscus, and tendons in HMWTg 
mice compared to VectorTg at 2 and 8 months of age (Fig. 8B). Similarly, FGF23 protein 
expression was markedly increased within the articular cartilage and subchondral bone of 
HMWTg mice, notably in the developing osteophyte at 8 months (Fig. 8C).  
FGF2 and FGF23 signal through the receptors FGFR1 and FGFR3, which have also been 
implicated in OA disease. FGFR1 and FGFR3 mRNA expression was significantly increased in 
whole joints of 2-month-old HMWTg compared to the VectorTg mice (Fig. 9A & B). 
Immunostaining revealed that FGFR1 protein was localized in the articular cartilage and 
meniscus of the joints, and appeared to be increased in HMWTg knees, compared to those of 
VectorTg at 2 months of age and even more strikingly at 8 months of age compared to the 
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VectorTg control (Fig. 9C). Immunohistochemistry also showed that HMWTg and VectorTg 
knees had similar expression of FGFR3 protein, particularly within the articular cartilage, which 
was decreased at 8 months of age compared to 2 months for both genotypes (Fig. 9D). 
 
2.5 Discussion 
 Although there have been numerous studies describing FGF2 and its involvement in OA, 
we provide evidence, for the first time, that the HMW isoforms of FGF2 may be a key 
component that contributes to joint degeneration in mice. In this study we demonstrated that 
mice overexpressing the nuclear HMW FGF2 isoforms in bone spontaneously exhibit signs of 
osteoarthropathy as early as 2 months of age and continue to develop a phenotype that mimic the 
progression of OA in human XLH subjects (40, 41). This phenotype included skeletal 
abnormalities of the knee, such as thinning of subchondral bone followed by sclerosis and 
osteophyte formation, modifications in trabecular architecture, such as increased trabecular space 
and decreased trabecular number, thinning of the articular cartilage, upregulated expression of 
cartilage degrading enzymes, and defective mineralization within the joint. Moreover, key FGF 
family members including FGF2, FGF23, and FGFR1 were overexpressed throughout the knee 
joint tissue of HMWTg mice.  
 Conflicting studies have been published about the role of FGF2 in joint homeostasis and 
degeneration (17,18,21,24). This study, in which we show that bone targeted overexpression of 
FGF2 HMW isoforms is accompanied by joint degeneration in transgenic mice, is consistent 
with catabolic potential of FGF2 in OA (17,18,21,24), which we suggest is probably due to the 
HMW FGF2 isoforms. HMWTg mice displayed an increase in total FGF2 in articular cartilage, 
yet the overexpression of the HMW FGF2 isoforms is in osteoblastic lineage cells. This increase 
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in FGF2 within the cartilage may be driven by the overexpression of the HMW FGF2 isoform in 
the subchondral bone due to the crosstalk of the bone-cartilage unit. Previous reports suggest that 
products of OA subchondral bone can be secreted into the joint space and accessed by the 
articular cartilage via synovial fluid (66), and there is evidence to suggest that the HMW FGF2 
isoform can be released from the cell (67). Also, since the Hyp mouse has been found to develop 
degenerative osteoarthropathy (44)
 
and we reported that these mice have an increase in the 
HMW FGF2 isoforms in osteocytes, (38)
 
as do our HMWTg mice, this suggests that these HMW 
FGF2 isoforms are contributing to the OA-like phenotype in the Hyp mouse. We posit that the 
changes within the Hyp mouse joint are due in part to the HMW FGF2 isoforms and not the 
LMW FGF2 isoforms, as the knees from our LMWTg mice appeared to be nearly identical to 
those of the VectorTg control furthermore we reported that the LMWFGF2 isoform was not 
overexpressed in bones of the Hyp mouse (38).  
 HMWTg mice develop many similar characteristics of osteoarthropathy to those 
displayed by Hyp mice. Both HMWTg mice and Hyp mice (44) display thinning of articular 
cartilage without evidence of fraying, a hallmark of osteoarthropathy found in XLH subjects (40, 
41). HMWTg and Hyp mice have overall hypomineralization (68, 69), which may be 
contributing to the observed thin articular cartilage, as hypomineralization of the subchondral 
bone, is believed to contribute to the expansion of the tibial plateau in response to increased load 
in an OA knee, consequently causing articular cartilage to stretch (70), resulting in decreased 
thickness. HMWTg joints had an increase in alkaline phosphatase and type X collagen staining, 
particularly in the area of the deep zone, as well as, throughout the cartilage, suggesting there 
could be an advancement of the tidemark and subchondral bone, a common OA-like 
characteristic  (71, 72). Although there was increased alkaline phosphatase staining throughout 
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the articular cartilage in HMWTg mice, the von Kossa staining did not correspond to the alkaline 
phosphatase-positive chondrocytes, which was similarly observed in Hyp mice (44), implying 
that defective mineralization is occurring. Vascular invasion of articular cartilage usually 
accompanies the advancement of the tidemark, which was evident in Hyp mice (44), as well as, 
HMWTg mice, which displayed VEGF expression at the interface of the articular cartilage and 
subchondral bone. Angiogenesis was present in the articular cartilage, a typically avascular 
tissue, is another hallmark of joint degeneration and may contribute to endochondral osteophyte 
formation in HMWTg and Hyp joints. Generally, HMWTg and Hyp mice share many of the 
same phenotypic traits of osteoarthropathy that are common to humans with XLH. 
 Although there have been no studies investigating the subchondral bone trabecular 
architecture in the Hyp mouse, there is increasing evidence that articular cartilage and 
subchondral bone act together as a functional unit (66, 4). We reported modifications in 
subchondral bone of HMWTg mice that are consistent with many osteoarthritic models (4, 3),
 
including thinning of bone in younger ages and sclerosis in older mice, which is prominent in 
XLH subjects (41). Also, the BV/TV and trabecular number and thickness were decreased, while 
the trabecular spacing was increased within the epiphysis of the femur and tibia. Other studies 
have shown that these alterations of the subchondral bone lead to an imbalance in stress 
distribution on the articular cartilage, ultimately leading to its degeneration (73). Thus, the 
decrease in articular cartilage thickness that was observed in HMWTg mice could be due to the 
modification of the underlying bone caused by the overexpression of the HMW FGF2 isoforms 
in that area.  
 A differing characteristic between HMWTg and Hyp knee joints is the localization and 
level of expression of articular cartilage matrix degradative enzymes, which are typically 
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upregulated in degenerated joints.  However, MMP13 is reduced in the joints of Hyp mice even 
though they display signs of OA (44).
 
In contrast, unlike Hyp mice, MMP13 expression was 
significantly increased in the articular cartilage of our HMWTg mice at all ages, suggesting these 
mice develop a more prototypical form of osteoarthropathy than Hyp mice (44). This elevation 
of MMP-13 may be attributed to the increase in FGF2 expression we observed in HMWTg mice, 
particularly in the articular cartilage, as it has been shown that FGF2 stimulates MMP-13 
activation (17). HMWTg mice displayed increased ADAMTS5 protein expression within the 
articular cartilage and areas of the joint compared to VectorTg at all ages. However, at 2 months 
of age Adamts5 mRNA expression was not significantly increased between HMWTg and 
VectorTg mice (data not shown). The lack of change in Adamts5 mRNA may be due to the age 
at which the RNA was isolated (2 month old mice in our study). It should be noted that other 
studies have reported that Adamts5 mRNA expression is not changed in early-stage human OA 
cartilage but is significantly increased in late-stage degenerative joint disease (74).  
The data from our study suggests that HMW FGF2 isoform overexpression in 
osteoblastic lineage cells is contributing to the upregulation of cartilage degradative enzymes 
within the joint.   We therefore propose that the overexpression of the HMW FGF2 isoforms may 
be contributing to osteoarthropathy in HMWTg mice by shifting catabolic over anabolic activity 
in the joint, causing an imbalance in cartilage homeostasis.  
FGFR1 is known to have an important role in OA in humans and mice (25,26,75). We 
found that FGFR1 gene and protein expression were increased in HMWTg knees, which is 
similar to other studies in which FGFR1 expression is increased in human osteoarthritic 
chondrocytes (25).
 
Our observation is also consistent with reported effects of inhibition of 
FGFR1 signaling in murine articular cartilage, which attenuates OA progression (26).
 
Since 
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binding of FGF2 to FGFR1 leads to a cascade of events that are typically catabolic in articular 
chondrocytes, including activation of NF-κB, which we determined was increased in HMWTg 
joints, and MAPK pathways (76)
 
it is possible that FGF2 overexpression in our model stimulates 
matrix degradation and blocks natural anabolic functions, causing the premature and severe 
osteoarthropathy we have observed. FGF2 also binds to FGFR3 with high affinity (25) and 
activation of FGFR3 has been shown to have anabolic effects in articular cartilage (23, 27).
 
However, we found that similar patterns and levels of FGFR3 protein were present in the 
articular cartilage of HMWTg and VectorTg mice. Similarly, other studies have shown that 
FGFR3 expression is unchanged in mice that underwent surgical-induction of OA (77).  
However, FGFR3 is decreased in human osteoarthritic chondrocytes in vitro (25).
 
These studies 
emphasize the inconsistent and potentially distinct roles of FGFR1 and FGFR3 in joint 
homeostasis and degeneration.  Since FGF2 binds both FGFR1 and FGFR3, which have 
contrasting roles in cartilage homeostasis, the FGFR1/FGFR3 ratio is likely essential in the 
biological outcome of FGF2. Although we found an increase in FGFR3 gene expression in 
HMWTg joints, the ratio of FGFR1: FGFR3 gene expression was significantly greater than that 
found in VectorTg (data not shown). This was also seen in human OA articular chondrocytes 
compared to healthy chondrocytes (25). However, the increased FGFR3 gene expression 
observed in this study could also reflect the inclusion of extracts used for this analysis. Indeed, it 
has been found by microarray analysis that FGFR3 expression is significantly increased in the 
subchondral bone of rats with degenerative joint disease (77).
 
Additionally, FGFR3 gene 
expression in our study may be increased due to an early repair response in HMWTg mice, as the 
qPCR data is only for 2-month-old mice, and FGFR3 has been reported to promote anabolic 
activities in articular cartilage (27). Future studies examining FGFR3 gene expression in older 
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mice and in specific tissue types are needed to fully resolve the relationships between FGFR1, 
FGFR3 and FGF2 in the joint.  
 HMWTg mice phenocopy most traits in XLH subjects, which includes increased FGF23 
levels in serum and bone (38) and now similar osteoarthropathies (40, 41). Our lab has 
previously shown that the HMW isoforms of FGF2 modulate and co-localize with FGF23 in 
osteoblast and osteocytes in HMWTg mice (38).
 
Thus, HMW FGF2 isoforms may be 
contributing to OA through FGF23 signaling, as FGF23 expression is upregulated in human 
osteoarthritic chondrocytes (45), which has been determined to drive MMP-13 expression (46), 
and we also demonstrated that FGF23 protein and MMP-13 mRNA and protein expression was 
increased within the joint, including the cartilage of HMWTg mice. Previous studies have shown 
that the development of OA could be due to the activation of hypertrophic differentiation of 
articular chondrocytes (78) and multiple signaling pathways are responsible including growth 
factors, such as BMPS and IGF-1, cytokines such as IL-1β and transcription factors Hif, Nf-κB, 
and Sox9 (65). Furthermore, although Sox9 is a marker for chondroprogenitor cells, studies have 
shown there is an increase in Sox9 expression in human chondrocytes of early-stage OA (79), as 
well as, murine osteoarthritic cartilage, particularly in areas of developing osteophytes (80). 
Since we found a significant increase in the expression of genes of these pathways in HMWTg 
joints, the OA-like phenotype may be caused by changes in the subchondral bone as well as 
hypertrophic differentiation of chondrocytes due to modulation of these factors and signaling 
molecules.    
 In conclusion, transgenic mice with bone-targeted overexpression of HMW FGF2 
(HMWTg mice) developed OA-like characteristics that were not simply restricted to a single 
component of the joint. Although changes in articular cartilage occurred, modifications within 
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the subchondral bone were concurrently happening, likely due to the targeted overexpression of 
the HMW FGF2 isoforms in bone in this model. Further studies will be necessary in order to 
decipher the exact mechanism that causes this phenotype.  Overall, HMWTg mice will serve as a 
novel model for joint degeneration, particularly in the context of osteoarthropathy observed with 
XLH, which could be used in future studies aimed at better understanding the pathophysiology 
of osteoarthropathy and OA, and may offer new insight into how to treat this disabling disorder.   
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2.6 Figures 
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Figure 2.6.1. Radiographic and MicroCT analysis of subchondral bone in VectorTg and  
HMWTg mice. A, Sagittal digital x-ray images of HMWTg knees show flattening of tibial 
plateau (open arrow), thinning of subchondral bone (open arrowhead), osteophyte formation 
(filled arrowhead), patellofemoral space narrowing (dashed arrow), and sclerotic bone (filled 
arrow). N=4-11/group. B, High-resolution micro-computed tomography (μCT) images of 
representative sagittal sections of all HMWTg samples show decreased trabecular bone in the 
epiphyses, thinning of subchondral bone at 2 and 8 months of age (open arrowheads), flattening 
of tibial plateau at 8 months of age (open arrow), and thickened sclerotic bone at 18 months of 
age (filled arrowhead). Three-dimensional (3D) renderings reveal erosion and pitting of HMWTg 
knees (arrows) while VectorTg knees maintain a smooth contour. C-D, 3D morphometric 
parameters revealed a decrease in BV/TV, Tb.N, and Tb.Th and an increase in Tb.Sp in 2 and 8 
month old HMWTg femoral and tibial epiphyses compared to VectorTg. BV/TV, trabecular 
bone volume; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Th; trabecular 
thickness. Values are the means ± SD. *P  <0.05, **P <0.01, ***P<0.001, compared with 
VectorTg. N=3/group. 
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Figure 2.6.2. Proteoglycan content of VectorTg and HMWTg knees at 2, 8, and 18 months 
of age. A, Safranin-O stained representative images showed a decrease in cartilage thickness in 
all HMWTg samples. B, 18-month-old HMWTg knees showed severe cartilage loss and 
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osteophyte development of mineralized cartilage (arrow) of femur. Bar = 200 μm.  C, Mean 
lateral tibial articular cartilage thickness of VectorTg and HMWTg. Values are the means ± SD, 
n=3-4/group. 
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Figure 2.6. 3. GFP expression in the frontal section of knees of 1-month-old VectorTg and 
HMWTg mice. VectorTg mice created with the Col3.6-IRES/GFPsaph construct and HMWTg 
mice created with the Col3.6-HMW Fgf2 isoforms-IRES-GFP construct reveal expression of any 
GFP in the same location (area of bone), while GFP expression was overall increased in 
HMWTg. The outlined white area is the corresponding box below, which is at a higher 
magnification. This area of the lateral left side of the knee shows no GFP expression in articular 
cartilage (dashed arrow) or tendon and meniscus regions. Nuclear stain (blue): To-Pro-3. 
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Figure  2.6.4. VectorTg and LMWTg knees at 19 months of age are phenotypically similar. 
A, Representative digital x-ray images show a comparable subchondral bone appearance in 
VectorTg and LMWTg knees. N=4/group. B, Safranin-O stained representative images show a 
similar cartilage phenotype and cartilage thickness in VectorTg and LMWTg samples. C, There 
was no difference between the mean lateral tibial articular cartilage thickness of VectorTg and 
LMWTg samples. Values are the means ± SD, n=3/group. 
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Figure 2.6. 5. Matrix metalloproteinase 13 (MMP-13), a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS-5), and type X collagen (Col X) expression in 
knees of VectorTg and HMWTg. A, Extraction of total RNA from knees of 2-month-old 
VectorTg and HMWTg and quantification of Mmp-13, Adamts5 and ColX mRNA by real time 
reverse transcription-PCR (qPCR).  Values are the means ± SD. *P  <0.05, n=7-8/group. B-C, 
Representative immunohistochemical staining of VectorTg and HMWTg knees at 2, 8, and 18 
months show increased protein expression of MMP-13 and ADAMTS-5 along articular cartilage 
(arrows). MMP-13 expression was increased in the enlarged tendon area of HMWTg joints at 2 
months of age (filled arrowhead) and in the developing osteophyte region of HMWTg joints at 8 
months of age (red arrow). Increased MMP-13 expression at 18 months within area of tendon 
was present in HMWTg (filled arrowheads) and absent in VectorTg (open arrowhead). D, 
RNAscope shows increased Col X expression throughout the articular cartilage in HMWTg 
(arrows) compared to VectorTg mice. Magnification = 20X. For IHC/RNAscope n=3-4/group.  
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Figure 2.6. 6. NF-κB and Sox9 mRNA and protein expression in knees of 2-month-old 
VectorTg and HMWTg. A, HMWTg knee joints have increased expression of NF-κB and Sox9 
mRNAs. Values are the means ± SD. *P  <0.05, ***P<0.001, n=7-8/group. B, Representative 
immunohistochemical staining of HMWTg knees shows phospho-NF-κB p65 expression 
throughout the articular cartilage (arrows), while no expression is present in VectorTg samples. 
C, Representative images show increased expression of SOX9 along articular cartilage (arrows) 
and meniscus of HMWTg joints, while there is relatively low expression in VectorTg joints. 
Magnification= 10X; n=3/group. 
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Figure 2.6.7.Comparison of VEGF, von Kossa, and alkaline phosphatase staining in 2-
month-old VectorTg and HMWTg knees. A, HMWTg knee joints show VEGF expression 
(arrows) in the subchondral bone and at the interface of the articular cartilage and subchondral 
bone. No cells were labeled for VEGF in VectorTg knee sections. B, Representative alkaline 
phosphatase staining of knees from HMWTg shows more alkaline phosphatase-positive articular 
chondrocytes (arrows) compared to VectorTg. C, Corresponding von Kossa stained sections 
reveal a decrease in mineral deposition despite the presence of alkaline phosphatase-positive 
chondrocytes in HMWTg knees, relative to VectorTg knees. Magnification= 10X; n=3/group. 
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Figure 2.6.8. Fgf2 and Fgf23 mRNA and protein expression in knees of VectorTg and 
HMWTg mice. A, Fgf2 and FGF23 mRNA levels were increased in 2-month-old HMWTg 
knees compared with VectorTg. Values are the means ± SD. **P <0.01, n=7-8/group. B, 
Representative immunohistochemical staining of FGF2 in 2 and 8 month old HMWTg articular 
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cartilage is increased (arrows). C, FGF23 protein expression is increased in 2 and 8 month old 
HMWTg articular cartilage (arrows) and bone (arrowheads). For IHC n=3-4/group; Bar = 50 μm.  
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Figure 2.6.9. FGFR1 and FGFR3 expression in knees of HMWTg and VectorTg mice. A-B, 
FGF2 and FGF23 mRNA level was significantly increased in HMWTg knees at 2 months of age. 
Values are the means ± SD. *P  ≤ 0.05, **P <0.01, n=7-8/group. C, Representative 
immunohistochemical staining of FGFR1 was more robust in HMWTg cartilage at 2 and 8 
months (arrows). D, Immunohistochemical staining of FGFR3 reveals similar protein expression 
within articular cartilage of VectorTg and HMWTg at 2 and 8 months (open arrows). For IHC 
n=3-4/group; Bar = 50 μm.  
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Table 2.6.1. Antibody Table 
Peptide/Protein 
Target 
 
Name of 
Antibody 
Manufacturer/
Catalog 
Number 
Species Raised 
(Monoclonal/Polyclonal) 
Dilution 
MMP13 Anti-MMP13 
antibody 
 
Abcam, ab39012 Rabbit;polyclonal 1:100 
ADAMTS5 Anti-
ADAMTS5 
antibody 
 
Abcam, ab41037 Rabbit;polyclonal 1:100 
FGF-2 FGF-2 (147) 
 
Santa Cruz, sc-
79 
 
Rabbit;polyclonal 1:50 
FGFR-3 p-FGFR-3 
(Tyr 724) 
 
Santa Cruz, sc-
33041 
Rabbit;polyclonal 1:100 
VEGF VEGF (A-20) 
 
Santa Cruz, sc-
152 
Rabbit;polyclonal 1:100 
FGF-23 Anti-FGF-23 
antibody 
 
R & D Systems, 
MAB26291 
Rat;Monoclonal 1:100 
FGFR-1 
NF-κB 
 
 
SOX9 
Flg (C-15) 
Anti-NF-κB 
p65 
(phospho- 
S536) 
antibody 
 
SOX9 
antibody 
Santa Cruz, sc-
121 
Abcam, 
ab131109 
 
 
Abcam, ab59265 
Rabbit;polyclonal 
Rabbit;polyclonal 
 
 
Rabbit;polyclonal 
1:50 
1:100 
 
 
1:50 
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Table 2.6.2. Primers used in qRT-PCR 
Gene Forward Reverse 
β-actin 5’-atggctggggtgttgaaggt-3’ 5’-atctggcaccacaccttctacaa-3’ 
Mmp-13 5’-ctttggcttagaggtgactgg-3’ 5’-aggcactccacatcttggttt-3’ 
Adamts5 5’-cctgcccacccaatggtaaa-3’ 5’-ccacatagtagcctgtgccc-3’ 
Col10a1 5’-gggaccccaaggacctaaag-3’ 5’-gcccaactagacctatctcacct-3’ 
Vegf 5’-gcacatagagagaatgagcttcc-3’ 5’-ctccgctctgaacaaggct-3’ 
Fgf2 5’-gtcacggaaatactccagttggt-3’ 5’-cccgttttggatccgagttt-3’ 
Fgf23 5’-acttgtcgcagaagcatc-3’ 5’-gtgggcgaacagtgtagaa-3’ 
FGFR1 5’-gactgctggagttaatacca-3’ 5’-ctggtctctcttccagggct-3’ 
FGFR3 
Sox9 
Nf-kb1 
Bmp-2 
Bmp-4 
Igf-1 
IL-1β 
Hif1α 
5’-gttctctctttgtagactgc-3’ 
5’-agtacccgcatctgcacaac-3’ 
5’-gaaattcctgatccagacaaaaac-3’ 
5’-agcgtcaagccaaacacaaacag-3’ 
 
5’-gccggagggccaagcgtagccctaag-3’ 
 
5’-gtgagccaaagacacaccca-3’ 
5’-gcaactgttcctgaactcaact-3’ 
5’-caagatctcggcgaagcaa-3’ 
 
 
5’-agtacctggcagcacca-3’ 
5’-acgaagggtctcttctcgct-3’ 
5’-atcacttcaatggcctctgtgtag-3’ 
5’-ggttagtggagttcaggtggtcag-3’ 
 
5’-ctgcctgatctcagcggcacccacatc 
-3’ 
5’-acctctgattttccgagttgc-3’ 
 
5’-atcttttggggtccgtcaact-3’ 
 
5’-ggtgagcctcataacagaagcttt-3’ 
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Table 2.6.3. Gene expression in knee joints of VectorTg versus HMWTg mice 
Gene VectorTg  HMWTg p-value 
Bmp-2 0.95 ± 0.28 1.56 ± 0.59 0.003 
Bmp-4 1.35 ± 0.50 2.68 ± 1.53 0.008 
Igf-1 1.52 ± 0.64 2.59 ± 1.62 0.041 
IL-1β 1.16 ± 0.41 2.08 ± 1.06 0.005 
Hif1α 1.29 ± 0.47 2.52 ± 1.54 0.008 
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3.1 Abstract 
FGF2 is an essential growth factor implicated in osteoarthritis (OA), and deletion of full-
length FGF2 leads to murine OA. However, the FGF2 gene encodes both high-molecular-weight 
(HMW) and low-molecular-weight (LMW) isoforms, and the effects of selectively ablating 
individual isoforms, as opposed to total FGF2, has not been investigated in the context of OA. 
We undertook this study to examine whether mice lacking HMW FGF2 (Fgf2
HMWKO
) or LMW 
FGF2 (Fgf2
LMWKO
) develop OA and to further characterize the observed OA phenotype in 
Fgf2
ALLKO
 mice. Fgf2
HMWKO
 mice never developed OA, but 6- and 9-month-old Fgf2
LMWKO
 and 
Fgf2
ALLKO
 mice displayed signs of OA, including eroded articular cartilage, altered subchondral 
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bone and trabecular architecture, and increased OA marker enzyme levels. Even with mechanical 
induction of OA, Fgf2
HMWKO
 mice were protected against OA, while Fgf2
LMWKO
 and Fgf2
ALLKO
 
displayed OA-like changes of the subchondral bone. Before exhibiting OA symptoms, 
Fgf2
LMWKO
 or Fgf2
ALLKO
 joints displayed differential expression of genes encoding key regulatory 
proteins, including IL-1β, insulin-like growth factor 1, bone morphogenetic protein 4, hypoxia-
inducible factor 1, B-cell lymphoma 2, Bcl2- associated X protein, a disintegrin and 
metalloproteinase with thrombospondin motifs 5, ETS domain–containing protein, and sex-
determining region Y box 9. Moreover, Fgf2
LMWKO
 OA cartilage exhibited increased FGF2, 
FGF23, and FGFR1 expression, while Fgf2
HMWKO
 cartilage had increased levels of FGFR3, 
which promotes anabolism in cartilage. These results demonstrate that loss of LMW FGF2 
results in catabolic activity in joint cartilage, whereas absence of HMW FGF2 with only the 
presence of LMW FGF2 offers protection from OA.  
 
3.2 Introduction 
Osteoarthritis (OA) is the most common form of joint disease and a leading cause of 
chronic disability worldwide, characterized by overall joint degeneration, primarily of the knee 
(1). Specific hallmarks of OA include articular cartilage degeneration (82), osteophyte formation 
(3), and dynamic modification of trabecular architecture of the underlying bone characterized by 
thinning subchondral bone in early stages of OA disease due to an increase in bone resorption 
with subsequent sclerosis of bone in later stages (4). In the articular cartilage, excessive catabolic 
activity results in matrix degradation via upregulation of metalloprotease enzymes, including 
matrix metalloproteinase 13 (MMP-13) and a disintegrin and metalloproteinase with 
thrombospondin motifs 5 (ADAMTS-5) (8,9,82).
 
The pathogenic mechanisms that underlie these 
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morphological phenotypes remain largely unknown. There is an urgent need for additional 
studies in order to identify therapeutic targets to prevent and treat OA disease, as there are 
currently no effective treatment options beyond total joint replacement (17). 
 Recently, the involvement of members of the fibroblast growth factor (FGF) family, 
particularly FGF2, has received considerable attention in the regulation of cartilage and joint 
homeostasis (18,21).
 
There is conflicting evidence which demonstrates both catabolic and 
anabolic potential of FGF2 in the joint. Specifically, exogenous FGF2 simulates MMP-13 and 
ADAMTS-5 production in articular cartilage explants in vitro (18,24)
 
and the level of FGF2 in 
OA synovial fluid is nearly twice that of healthy knees (21), suggesting catabolic functions. 
Conversely, Fgf2 knockout (Fgf2
ALLKO
) mice develop spontaneous and surgically-induced OA 
more frequently and severely than their wild type (WT) littermates (24), suggesting an anabolic 
role for FGF2 in the joint. Additional studies are clearly necessary to further define the role that 
FGF2 plays in joint homeostasis and potentially in OA etiology.  
Importantly, the FGF2 gene encodes multiple protein isoforms including the high 
molecular weight (HMW) isoforms and the low molecular weight (LMW) isoform.  The LMW 
isoform is translated from the traditional AUG start codon, while the HMW isoforms are 
initiated upstream of the LMW start site from individual CUG codons (29). In humans there are 
three HMW FGF2 isoforms (22, 22.5, 24kDa), and in rodents there are two HMW FGF2 
isoforms (21, 22kDa).  The HMW FGF2 isoforms contain a nuclear localization sequence and 
remain in the nucleus to function as an intracrine factor (36). In humans and rodents there is one 
LMW FGF2 isoform, which is transported out of the cell to function as an autocrine/paracrine 
growth factor (37). Although deletion of full-length FGF2 leads to OA, the implications of 
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separately ablating the individual isoforms in joint homeostasis and potentially in OA 
pathogenesis has not been addressed. 
In this study we investigated if selectively deleting the HMW or LMW isoforms would 
affect the OA phenotype. Mice with a deficiency of HMW FGF2, Fgf2
HMWKO
 mice, were 
previously generated and characterized (36) and of importance had increased bone mineral 
density (BMD) compared to WT mice (37). In a similar manner mice lacking LMW FGF2, 
Fgf2
LMWKO
 mice, were generated and previously characterized (33) and found to have decreased 
BMD compared to WT mice (34).  We have recently shown that mice that overexpress the 
HMW FGF2 isoforms develop degenerative joint disease (83), so we hypothesized that 
Fgf2
LMWKO
 mice (which only express the high molecular weight FGF2 isoform), but not 
Fgf2
HMWKO
 mice, would develop OA.  The aim of our study was to examine Fgf2
HMWKO
 and 
Fgf2
LMWKO
 mice for any evidence of spontaneous and mechanically-induced OA, while 
confirming and further characterizing the OA phenotype in Fgf2
ALLKO
 mice. The results of this 
novel study are of particular importance given the contrasting data of the involvement of FGF2 
in OA, and for the first time show the differing effects of the distinct isoforms in the 
development of the disease. 
3.3 Materials and Methods 
 
3.3.1 Animals 
 Fgf2
ALLKO 
mice were previously developed on a Black Swiss 129Sv background (19) and 
genotyping was performed using primers as previously described (84,35). Fgf2
HMWKO
 mice were 
formerly generated on a at the GEMM Core at the University of Arizona by gene-targeted 
introduction of polymorphisms, using a Tag and Exchange strategy, to remove the alternative 
51 
 
CUG codon start sites required to translate the HMW isoforms of FGF2 (14) and genotyping was 
performed using primers previously described (36). Fgf2
LMWKO
 mice were generated in a similar 
manner to remove the ATG translational start site (33), and genotyping was performed using 
primers previously described (33). All mice were developed on a Black Swiss 129Sv background 
and deletion of the gene or selective isoform is constitutive. Heterozygote mice for each 
genotype were bred and housed in the transgenic facility in the Center for Comparative Medicine 
at UConn Health and all experiments were performed with littermate controls. Unless otherwise 
indicated, all data presented involved male mice. The UConn Health Institute of Animal Care 
and Use Committee approved all animal procedures.   
 
3.3.2 Radiological analyses and Micro-computed tomography 
 Digital x-ray images of murine knee joints taken in the sagittal and frontal planes were 
obtained with a SYSTEM MX 20 from Faxitron X-ray Corporation (Faxitron X-ray Corp., 
Wheeling, IL) and taken under constant conditions (26 kV at 6-s exposure). Imaging of knee 
architecture was performed using ex vivo micro-computed tomography (μCT40, ScanCo Medical 
AG, Bassersdorf, Switzerland). 
 
3.3.3 Histologic Assessment 
Mice were sacrificed utilizing the approved CO2 method for euthanasia and whole knee 
joints were removed, fixed in 4% paraformaldehyde for 6 days, and decalcified with 14% EDTA 
solution at 4°C. Samples were processed for paraffin embedding in a frontal orientation and 7-
μm alternate sections were obtained. Following de-paraffinization and rehydration of the 
sections, Safranin-O staining of glycosaminoglycans was performed using 0.1% aqueous 
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Safranin-O and counterstained with Weigert’s Iron Hematoxylin and 0.02% aqueous Fast Green. 
Additional tissue sections were stained with hematoxylin and eosin (H&E). All histological 
images were captured using Nikon TS100 microscope interfaced with SPOT software. Using 
Safranin-O stained sections, the severity of cartilage destruction was assessed histologically by a 
single observer blinded with regard to the mouse group using the recommended scoring system 
from Glasson et al. (85) (0= normal; 0.5= loss of proteoglycan without structural changes, 1= 
small fibrillation without cartilage loss, 2= vertical clefts down to layer directly beneath 
superficial layer/some loss of surface lamina, 3= vertical clefts/erosion down to calcified 
cartilage layer which extends  <25% of articular surface, 4= vertical clefts/erosion down to 
calcified cartilage layer which extends 25-50% of articular surface, 5= vertical clefts/erosion 
down to calcified cartilage layer which extends 50-75% of articular surface, 6= vertical 
clefts/erosion down to calcified cartilage layer which extends  >75% of articular surface). 
Scoring was performed on all articular surfaces within each section using 4 separate 
representative sections from each knee, closest to the center of the joint, from 5 different samples 
from each genotype. The mean score of the medial tibial plateau (n=5/group) or mean overall 
(n=4-5/group) score was reported.  
Histomorphometric measurements were made in the same blinded, nonbiased manner, 
using the OsteoMeasure image analysis system (R & M Biometrics, Nashville, TN) equipped 
with a Nikon E400 microscope (Nikon Inc., Melville, NY). The region of subchondral trabecular 
bone of the epiphysis in the femur and tibia, was previously established (86), and analyzed for 
the following histomorphometric parameters: bone volume/tissue volume (BV/TV), trabecular 
thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular number (Tb.N), using 3 
representative samples closest to the center of the joint from each different genotype.  
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3.3.4. Immunohistochemistry  
Immunohistochemical staining was performed on 7-μm paraffin embedded sections using 
the ImmunoCruz™ ABC Staining System (Santa Cruz Biotechnology, CA, USA). After sections 
were de-paraffinized and rehydrated, slides underwent antigen retrieval by incubation at 95°C 
with 10mM sodium citrate buffer for 10 minutes and then cooled to room temperature for 30 
minutes. Endogenous peroxidase activity was then blocked by incubating sections with 3% 
hydrogen peroxide in water for 15 minutes. Following blocking sections with 10% serum for one 
hour at room temperature, the slides were incubated with primary antibodies in blocking buffer 
overnight at 4°C. A negative control slide was used each time, which was instead incubated with 
blocking serum overnight. The following primary antibodies were used: rabbit anti-MMP13, 
1:100 (Abcam, ab39012), rabbit anti-ADAMTS5, 1:100 (Abcam, ab41037), rabbit anti-FGF2, 
1:50 (Santa Cruz, sc-79), anti-FGF-23, 1:100 (R & D Systems, MN, USA, MAB26291), rabbit 
anti-FGFR-1 (Flg C-15)1:50 (Santa Cruz, sc-121),  rabbit anti-pFGFR-1, 1:50 (Abnova, 
PAB0471), rabbit anti-pFGFR-3 (Tyr 724), 1:100 (Santa Cruz, sc-33041), and rabbit anti-
phosphop44/42 MAPK (Cell Signaling, 4376S). After washing with TBS containing 0.1% 
Tween 20, the appropriate 1:200 biotinylated secondary antibody was applied at room 
temperature for 30 minutes. Finally, slides were washed and developed with DAB Peroxidase 
Substrate kit (Vector Laboratories, Burlingame, CA, USA), and counterstained with Harris 
hematoxylin. 
3.3.5. Mechanical Induction of OA 
Under isoflurane-induced anesthesia, mice were subjected to a single session of external 
compressive loading of the right tibiae, while left legs served as contralateral controls.  The 
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electromagnetic loading machine (ElectroForce 3100; Bose Co., Eden Prairie, MN, USA) 
applied a peak load level of 9.5N at a frequency of 4Hz for 1,200 cycles (5 min) and mice were 
sacrificed 2 weeks after mechanical compression and intact knees were fixed in 4% 
paraformaldehyde. This mechanical loading protocol was previously demonstrated to induce 
OA-like cartilage and bone alterations 2 weeks after loading (16).  
 
3.3.6. RNA isolation and real time PCR 
Total RNA was isolated from whole knee joints, to include all structures of the joint 
above the growth plate, following skin and bulk muscle removal from 2 month old male mice 
from all genotypes, in a method previously described (24). Following snap-freezing by liquid 
nitrogen, TRIzol reagent (Invitrogen) was used to extract RNA from the tissue. For real-time 
quantitative RT-PCR (qRT-PCR) analysis, RNA was reverse-transcribed to cDNA using RNA to 
cDNA EcoDry Premix kit (Clontech Inc., A Takara Bio Company). A Bio-Rad MyiQ
TM
 
 instrument (BIO-RAD Laboratories Inc. Hercules, CA) using iTaq
TM
 Universal SYBR Green 
Supermix (Bio-Rad, CA, USA) was utilized for qPCR. The relative change in mRNA level was 
normalized to the mRNA level of beta-actin (β-actin), a housekeeping gene, which served as an 
internal reference for each sample. Table 1 lists the primers, synthesized by IDT (Integrated 
DNA Technologies, Inc., CA), for the genes of interest. N=6-8/group. 
  
 
3.3.7. Statistical analysis 
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Data is presented as mean ± standard deviation (SD). Student’s t-test was used to analyze 
differences between groups and considered significant at p values less than 0.05, unless 
otherwise stated. 
 
3.4 Results 
 
3.4.1. Radiographic phenotype of joints of male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type 
littermates  
 Digital radiographic examination revealed no abnormalities of the subchondral bone of 
the knee in all 2 months old samples of Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and WT littermate 
controls (Fig. 1). At 6 months of age all (10 of 10) Fgf2
ALLKO
 and (9 of 9) Fgf2
LMWKO
 knee joints 
displayed evidence of joint destruction, flattening of tibia, and osteophyte formation on the 
posterior tibial plateau compared to the WT controls. These OA-like alterations were also 
evident in 9 months old Fgf2
ALLKO
 (4 of 4) and Fgf2
LMWKO 
(8 of 8), while Fgf2
HMWKO 
knees were 
phenotypically similar to WT at all ages and showed no radiographic indications of OA (Fig. 1). 
X-rays of knees in female mice displayed the same result as males of all genotypes (data not 
shown), indicating that gender does not influence the OA phenotype in these mice. 
 
3.4.2. Histological phenotype of knees of male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type 
littermates 
Articular cartilage integrity was determined histologically by Safranin-O staining in 2, 6, and 9 
months old Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and WT littermate controls. At 2 months of age 
there was no difference in proteoglycan content, cartilage thickness, or Safranin-O intensity 
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between Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and WT knees. By 6 and 9 months of age, both 
Fgf2
ALLKO
 and Fgf2
LMWKO 
joints showed spontaneous fibrillation of cartilage (arrowheads), areas 
of complete cartilage loss (arrows), and evidence of osteophyte formation (Fig. 2A). Safranin-O 
stained Fgf2
HMWKO 
cartilage appeared to have similar cartilage integrity to the WT at all ages 
(Fig. 2A). The severity of cartilage destruction and extent of chondral damage was graded in 6 
months old samples from at least 20 Safranin-O sections from the joint, per group (see 
Experiment Procedures) and the average score of the medial tibial plateau was reported. The 
score of Fgf2
ALLKO 
was significantly higher than WT, p=.002 and Fgf2
LMWKO 
was significantly 
higher than the WT littermate, p=.004. The histologic score showed no significant difference 
between Fgf2
HMWKO
 and WT, p=.126 (Fig. 2B).  Also, H & E-stained 6 month old Fgf2
LMWKO   
joints showed inflammation in the medial tendon and synovium and enlarged meniscus, which 
was not present in WT littermates or Fgf2
HMWKO
 and WT littermates (Fig. 2C). Fgf2
ALLKO 
H & E-
stained sections showed cartilage loss, but less evidence of inflammation (Suppl. Fig. 1A). 
 
3.4.3. Micro-computed tomography and histomorphometric analyses of male Fgf2
HMWKO
, 
Fgf2
LMWKO
, and wild-type littermate knees 
 Reconstructed 3D images of 6 months old Fgf2
LMWKO 
joints display bony outgrowths 
(closed arrowheads), indentations, and wearing away of the tibial surface (open arrowhead), 
while the Fgf2
HMWKO
 renderings show a smooth and flat shape of the subchondral surface which 
was consistent with both types of WT littermates (Fig. 3A). MicroCT-scanned 2D images show 
tibial osteophyte formation and thinning of subchondral femoral bone (dashed arrow) of 
Fgf2
LMWKO
 compared to the WT (arrow). The Fgf2
LMWKO
 images also display alterations in the 
trabecular architecture in the femoral and tibial epiphyses, particularly evident in the sagittal 
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view, which includes loss of trabeculae and increased spacing between trabeculae. These OA 
characteristics were not observed in the Fgf2
HMWKO
 or WT littermates (Fig. 3A). 
Histomorphometry revealed there was no significant difference between bone volume/tissue 
volume (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and trabecular 
number (Tb.N) in both of the epiphyses of the femur and tibia between Fgf2
HMWKO
 or WT 
littermates (Fig. 3B). However, the BV/TV of the femoral epiphyses was 50% less (p< .001) in 
the Fgf2
LMWKO
 compared to the WT and 47% less (p< .001) in the tibia. Tb.Th was significantly 
lower in Fgf2
LMWKO
 compared to the WT in the femur (p=.014) and tibia (p=.004). The Tb.Sp of 
the Fgf2
LMWKO
 epiphysis was significantly increased in the femur and tibia by 96% (p< .001) and 
61% (p< .001) respectively, compared to that of the WT. Also, there was a 39% reduction (p< 
.001) in Tb.N. of the femoral epiphysis and a 33% reduction (p=.001) in the tibia of the 
Fgf2
LMWKO
 compared to the WT (Fig.3C). The findings were similarly significant in 6 month old 
Fgf2
ALLKO 
epiphyses (Suppl. Fig. 1B). By histomorphometry, at 2 months of age the BV/TV, 
Tb.Th, Tb.Sp, and Tb.N of the epiphysis of both the femur and tibia was not significantly 
different between all genotypes and the littermate WT controls (Suppl. Fig. 2). 
 
3.4.4. Expression of OA markers in male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type 
littermates 
 Immunohistochemistry was used to examine the presence of OA marker protein 
expression within the joint tissues. At 6 months of age, MMP-13 (a collagenase) was greatly 
enhanced within the articular cartilage of the Fgf2
ALLKO
 and Fgf2
LMWKO 
compared to the WT, 
whereas, Fgf2
HMWKO 
cartilage had comparable MMP-13 staining to that of the WT littermate 
(Fig. 4A). ADAMTS-5 (the major aggrecan degrading enzyme in murine cartilage) was also 
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increased throughout the tissues of the joints of 6-month-old Fgf2
ALLKO
 and Fgf2
LMWKO
, 
particularly in the enlarged medial meniscus and tendon area and developing osteophyte region 
of Fgf2
LMWKO
. Examining the same area of the Fgf2
HMWKO 
knee, immunohistochemistry revealed 
similar or slightly less ADAMTS-5 expression compared to WT (Fig. 4B).   
 
3.4.5. Examination of age induced OA in female Fgf2
HMWKO
, and mechanically-induced OA in 
male Fgf2
HMWKO
, Fgf2
LMWKO
, and wild-type littermates 
 In order to determine if Fgf2
HMWKO 
mice are protected from age-related OA, we examined 
knees of 2-year-old female Fgf2
HMWKO 
mice (n=6). The x-ray images of WT joints appeared to 
have some evidence of sclerotic bone formation, while the Fgf2
HMWKO 
joints did not (Fig.5A). 
Safranin-O staining showed a loss of proteoglycan content, a decreased superficial zone layer, 
and slight fraying of cartilage in WT sections, while this was not observed in Fgf2
HMWKO 
cartilage. The total joint OA score was significantly increased in WT compared to Fgf2
HMWKO
 , 
p=.020 (Fig. 5A-B). Immunohistochemical staining of the OA marker, ADAMTS-5, showed 
little expression in tibial articular chondrocytes of Fgf2
HMWKO 
mice compared to the many 
labeled chondrocytes of the WT (Fig. 5C). It would be expected that mice aged to 2 years would 
display signs of OA. 
To further verify that Fgf2
HMWKO 
mice are protected from OA, we induced joint damage 
in 21 month old Fgf2
HMWKO 
and WT mice by subjecting the right leg to a single session of cyclic 
tibial loading, previously shown to induce OA-changes in 2 weeks after loading (86). The 3D 
and 2D microCT images of Fgf2
HMWKO  
right knees showed no indications of OA in the 
subchondral bone and had a similar phenotype to that of the left contralateral control and the 
right and left legs of the WT (Fig. 5D). In order to determine if challenging Fgf2
LMWKO 
knees will 
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accelerate the OA phenotype, right legs of approximately 12 week old Fgf2
LMWKO 
mice 
underwent the same tibial loading procedure. Two weeks after loading, 3D microCT images of 
the right leg show an uneven tibial surface and evidence of erosion compared to the smooth 
surface observed in the left contralateral control and in both knees of the WT littermates. The 
sagittal view shows thinning of subchondral bone, loss of trabeculae and increased trabecular 
spacing in the epiphyses compared to the left control (Fig. 5E). To confirm the validity of the 
mechanically-induced OA model the same protocol was carried out on Fgf2
ALLKO  
knees, which 
have previously shown to have accelerated OA following surgical induction (24), and 2 weeks 
after loading the microCT images revealed similar OA-like changes in the right leg that were 
observed in Fgf2
LMWKO
 mice (Suppl. Fig. 1C). 
Histologically, 21 months old WT joints that underwent tibial loading showed signs of 
cartilage damage, whereas, the contralateral controls and Fgf2
HMWKO 
joints (both loaded and non-
loaded) did not exhibit evidence of OA, and is reflected in the scores of the medial tibial plateau 
(Fig. 5F). Safranin-O staining of right loaded knees of 12 weeks old Fgf2
LMWKO
 mice revealed 
fibrillation of tibial cartilage and decreased size of the superficial zone. The histologic score of 
loaded Fgf2
LMWKO
 knees was significantly higher than the controls (Fig. 5G).   
 
 
3.4.6. Expression of OA-like genes in male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type 
littermates  
 Total RNA was isolated from knee joints of 2 month old Fgf2
ALLKO
, Fgf2
HMWKO
, 
Fgf2
LMWKO
, and their WT littermates and used for measuring mRNA levels of genes that have 
been implicated in OA, including cytokines, growth factors, and components involved in OA-
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like changes in subchondral bone or hypertrophy of chondrocytes. qPCR analysis showed 
significant increases in the mRNA from both Fgf2
ALLKO
and Fgf2
LMWKO
 knees for interleukin 1 
beta (Il-1β), insulin like growth factor 1(Igf1), bone morphogenetic protein 4 (Bmp4), hypoxia 
inducible factor 1(Hif1α), and the ratio of B-cell lymphoma 2 (Bcl2) and Bcl2-Associated X, 
apoptosis regulator (Bax), while Fgf2 was significantly increased in Fgf2
LMWKO
 knees and 
decreased in Fgf2
ALLKO
 knees (Fig. 6A). We also observed significant increases in the mRNA 
from only Fgf2
ALLKO
 knees for Adamts5, ETS domain-containing protein-1 (Elk-1), Sex 
determining region Y box 9 (Sox9), and FGFR1 (Fig. 6B). qPCR showed increases in the mRNA 
from only Fgf2
LMWKO
 knees for vascular endothelial growth factor (Vegf), type X collagen 
(ColX), FGFR3, and Fgf23 (Fig. 6C). The expression of Fgf23 was too low to be detected in 
Fgf2
ALLKO 
joints and mRNA expression of any gene of interest was not significantly modulated in 
Fgf2
HMWKO
 joints compared to WT. 
 
3.4.7. Expression of FGF ligands and receptors in knees of male Fgf2
ALLKO
, Fgf2
HMWKO
, 
Fgf2
LMWKO
, and wild-type littermates 
 Immunohistochemistry confirmed that Fgf2
ALLKO
 joints did not have FGF2 expression, as 
shown by the absence of any labeled cells in the articular cartilage compared to the WT 
littermate at 2 and 6 months of age (Fig. 7A&B). Fgf2
HMWKO 
cartilage had similar FGF2 
expression to the WT at 2 months of age (Fig.7A), but appeared to have decreased FGF2 
expression by 6 months of age (Fig. 7B). However, Fgf2
LMWKO
 articular cartilage showed 
enhanced FGF2 expression at 2 and 6 months of age (Fig.7A&B) compared to the WT littermate. 
Localization of the protein confirmed that FGF2 was detected in the cytoplasm and the nuclei of 
chondrocytes in Fgf2
HMWKO 
joints, similarly to the WT, whereas FGF2 was only detected in the 
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nuclei of Fgf2
LMWKO 
chondrocytes and not present in Fgf2
ALLKO
 tissue (Fig. 7C). Immunostaining 
revealed increased FGF23 protein expression in Fgf2
LMWKO
 articular cartilage at 2 months of age 
compared to WT, while cartilage of Fgf2
ALLKO
and Fgf2
HMWKO 
had similar FGF23 expression to 
that of the WT (Fig. 8A). By 6 months of age immunostaining displayed enhanced FGF23 
expression in Fgf2
ALLKO
 along the articular surface compared to WT and Fgf2
LMWKO
 maintained 
high FGF23 expression compared to WT. Fgf2
HMWKO 
cartilage still had similar FGF23 
expression to the WT littermate (Fig. 8B). FGF2 and FGF23 signal through FGFR1 and FGFR3, 
which are known to be involved in OA etiology. At 6 months of age, articular chondrocytes had 
increased total FGFR1 expression in Fgf2
ALLKO
 knees and Fgf2
LMWKO
 joint tissues had increased 
total FGFR1 expression, notably in developing osteophyte regions and the inflamed tendon areas 
compared to the WT. Fgf2
HMWKO 
joints had similar total FGFR1 expression to that observed in 
WT (Fig. 9A). Phosphorylated FGFR1 expression was present in Fgf2
ALLKO
 cartilage and 
appreciably expressed in Fgf2
LMWKO 
chondrocytes (Fig. 9B). Conversely, at 6 months of age 
Fgf2
ALLKO
 and Fgf2
LMWKO
 knees had a marked decrease in phosphorylated FGFR3 expression as 
observed in articular cartilage in the femur (Fig. 9C). Also, phospho-FGFR3 protein expression 
was enhanced in knees of 6 months old Fgf2
HMWKO
 compared to WT cartilage (Fig. 9C). 
Expression of phospho-ERK1/2, a downstream component of FGF2/FGF23/FGFR signaling, 
was only present in Fgf2
LMWKO 
cartilage (Fig. 9D). 
 
3.5 Discussion 
 Though there have been several publications reporting the contribution of FGF2 in the 
progression of OA, including a previous study which showed that deletion of full-length FGF2 in 
mice leads to enhanced OA (24), we describe for the first time that the varying FGF2 isoforms 
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have differing roles in degenerative joint disease. In this study we demonstrated that mice 
lacking only the LMW FGF2 isoform (Fgf2
LMWKO
) develop signs of spontaneous and 
mechanically-induced OA, including cartilage destruction, inflammation, modifications of the 
subchondral bone, and upregulation of degradative enzymes. Fgf2
HMWKO 
mice appeared to be 
protected from OA, as they did not display these characteristics, despite age or mechanical 
induction. Moreover, Fgf2
ALLKO 
and Fgf2
LMWKO
 knees already had enhanced expression of genes 
involved in multiple signaling pathways known to promote OA at just 2 months of age, which 
preceded the OA phenotype. Also, essential FGF family members including FGF23 and FGFR1 
were upregulated in Fgf2
ALLKO 
and Fgf2
LMWKO
 joints, while FGFR3 was increased in Fgf2
HMWKO
 
cartilage. 
 Despite there being numerous contradictory findings about the involvement of FGF2 in 
cartilage homeostasis and degradation (18,21,24), this study supports the idea that FGF2 can 
have both an anabolic and catabolic effect dependent upon the presence or absence of the 
isoform. Fgf2
LMWKO
 mice displayed classic hallmarks of OA that began at 6 months of age, 
which persisted to 9 months of age and were not restricted to simply one component of the joint. 
Histological examination revealed frayed cartilage, areas of complete cartilage loss, and 
evidence of endochondral ossification of developing osteophytes, which was most apparent on 
the medial side. As indicated by the OA score, these destructive alterations of cartilage were not 
present in joints of Fgf2
HMWKO 
mice. Following mechanical induction the 21 months old WT 
littermates of Fgf2
HMWKO 
mice displayed histologic evidence of OA, as their age would make 
them more susceptible when challenged, whereas, the Fgf2
HMWKO 
mice appeared protected. Also, 
articular cartilage of Fgf2
LMWKO
 and Fgf2
ALLKO 
mice had increased expression of degradative 
enzymes, MMP-13 and ADAMTS-5, while Fgf2
HMWKO 
joints did not. Additionally, subchondral 
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bone was thinner, contained osteophytes, had a decrease in trabecular number and thickness and 
an increase in trabecular spacing in only Fgf2
LMWKO
 and Fgf2
ALLKO 
mice, indicating that this 
particular OA phenotype encompasses all joint tissues.  
 In order to determine if there are modifications of gene expression of pathways involved 
in OA induction before the disease phenotype occurs in Fgf2
LMWKO
 and Fgf2
ALLKO 
mice, RNA 
was isolated from whole knee joints at 2 months of age. It has been found that progression of OA 
may be caused by activation of hypertrophic differentiation of articular chondrocytes (78) and 
various signaling pathways are implicated which include cytokines such as Il-1β, growth factors 
such as IGF-1 and BMP4, and transcription factor Hif1α (65). Since joints from both Fgf2LMWKO 
and Fgf2
ALLKO 
mice were found to have significant increased expression in genes of those 
pathways, it suggests that in addition to the observed modifications of the underlying bone, that 
hypertrophic differentiation of articular chondrocytes is driving the OA phenotype. Typically, 
the Bcl2/Bax ratio is decreased in mRNA taken from OA cartilage, as the Bcl2 protein protects 
chondrocytes from cell death, while Bax accelerates apoptosis (87). However, it was found that 
Bcl2 expression declines with age, while Bax expression remains constant, suggesting that the 
shift of this ratio to favor apoptosis would only occur in cartilage with age (88). Thus, the young 
age in which we examined the Bcl2/Bax ratio in Fgf2
LMWKO
 and Fgf2
ALLKO 
knees may be why we 
did not observe a decrease.   
 Although Fgf2
ALLKO 
and Fgf2
LMWKO
 shared a similar OA phenotype and modulation of 
related genes, there were some differences that were observed, indicating that joint degeneration 
might not be caused by the equivalent mechanism, as the Fgf2
LMWKO
 mice still possess the HMW 
FGF2 isoforms. Through H & E staining we observed inflammation of the tendon and synovium 
in Fgf2
LMWKO
 knees, whereas this particular aspect was absent in Fgf2
ALLKO 
knees, which was 
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consistent with the previous study that examined OA in Fgf2
ALLKO 
mice and reported no evidence 
of synovitis (24). Also, the qPCR analysis showed some distinct differences in gene expression 
of mRNA taken from 2 month old joints of Fgf2
ALLKO
 and Fgf2
LMWKO
 mice. Fgf2
ALLKO
 joints 
already had significant increases in the catabolic enzyme Adamts5 and the transcription factor, 
Elk-1, which induces MMP-13 expression (89) and Sox9, which although is a chondroprogenitor 
marker, has been shown to be increased in human chondrocytes with early-stage OA (79). 
Fgf2
LMWKO 
mRNA did not have this early high expression of these genes, but instead had 
increased Vegf and ColX expression, signifying chondrocyte hypertrophy, another hallmark of 
OA cartilage.  
 As mentioned earlier there are numerous conflicting studies on the role that FGF2 plays 
in OA and this is mainly due in part to its binding affinity for FGFR1 and FGFR3, which have 
contrasting roles in cartilage homeostasis. While FGFR1 is increased in human OA 
chondrocytes, drives cartilage destruction (25), and its inhibition attenuates OA in murine 
cartilage (26), FGFR3 is decreased in human OA chondrocytes (25), promotes anabolic activity 
in cartilage (27), and its absence accelerates murine OA (28). Regardless of the essential absence 
of mRNA and protein expression of FGF2 in Fgf2
ALLKO
 joints, there was a significant increase in 
FGFR1 mRNA at 2 months of age and protein expression at 6 months of age. This early increase 
of FGFR1 expression could be due to enhanced expression of other FGF ligands, as many other 
than FGF2, bind to FGFR1, including FGF1 which has been shown stimulate catabolic effects in 
chondrocytes and was increased in OA tissues of rat and humans (90,91). Once the Fgf2
ALLKO
 
mice displayed signs of OA, the cartilage had increased expression of FGF23, which can bind to 
FGFR1 and is known to drive MMP13 expression in osteoarthritic chondrocytes (46). Also, the 
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expression of activated FGFR1 was not as great as the expression of total FGFR1, implying that 
the OA phenotype may be attributed to modulation of a different pathway. 
 Interestingly, Fgf2
LMWKO 
had increased FGF2 mRNA and protein expression at 2 months 
and increased protein expression still at 6 months of age, and while FGFR3 expression was 
enhanced at 2 months of age, phospho-FGFR3 was not detected at 6 months, yet total and 
phospho-FGFR1 expression was greatly increased.  This initial increase in FGFR3 may be an 
early repair response, as the RNA was taken at only 2 months of age and signaling through 
FGFR3 can promote anabolic activities in cartilage (27). Furthermore, FGF23 expression was 
increased at 2 and 6 months of age in Fgf2
LMWKO 
joints, which can also signal through FGFR1 to 
push the OA phenotype via regulation of the MEK/ERK cascade (46) and we observed enhanced 
phospho-ERK expression in only Fgf2
LMWKO
 only. Intriguingly, Fgf2
LMWKO 
knees showed 
upregulation of the same genes as mice that overexpressed the HMW FGF2 isoforms, including 
FGF23, which also developed degenerative joint disease (83), suggesting that lack of LMW 
FGF2 may be causing a compensatory effect, which would increase HMW FGF2, which is 
driving the OA phenotype and would explain the significant increase in FGF2 protein and 
mRNA. Mice that overexpress the LMW FGF2 isoform do not develop OA (83) and Fgf2
HMWKO 
mice were protected from OA despite age and mechanical induction and had an increase in 
FGFR3 expression at 6 months of age. Similarly, this suggests that it is the HMW FGF2 isoform 
responsible for the OA phenotype and that the presence (or possible overcompensation) of LMW 
FGF2 confers a chondroprotective effect.  
We demonstrated that chondrocytes of Fgf2
LMWKO 
expressed FGF2 solely and robustly in 
the nucleus, confirming that Fgf2
LMWKO 
mice only express HMW FGF2 since this isoform 
remains in the nucleus (36). Fgf2
HMWKO 
mice expressed FGF2 in the nucleus and cytoplasm, 
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having similar expression to WT. This data is consistent with previous investigators who showed 
that HMW FGF2 has nuclear localization and LMW FGF2 is expressed in cytoplasm and 
nucleus (29) and others who demonstrated that cardiomyocytes from Fgf2
LMWKO
 and Fgf2
HMWKO
 
mice have varying localization of FGF2 via immunohistochemistry (92) (as there are no 
commercially available antibodies to detect the isoforms). Notably, this study highlights the 
importance of the possible roles that each FGF2 variant may have in cartilage homeostasis, as the 
relative expression levels of the FGF2 isoforms in both adult human and murine healthy or OA 
cartilage is unknown. Though in fetal growth plate cartilage it was determined that LMW FGF2 
was only expressed in resting cartilage, whereas HMW FGF2 was expressed by proliferating 
chondrocytes (93). This evidence further supports the idea that HMW FGF2 is the isoform 
contributing to OA, since during OA the normally quiescent chondrocytes begin to proliferate, 
recapitulating a process that resembles chondrocyte differentiation during endochondral 
ossification (94).  
 Finally, our observations provide insight into the varying roles of FGF2 and its isoforms 
in OA and why global deletion of FGF2 leads to the disease. Though the exact molecular basis of 
the involvement of FGF2 isoforms still requires further investigation, this data offers a more 
thorough understanding of the potential future treatment or management of OA. 
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3.6 Figures 
 
 
Figure 3.6.1. Time course of radiographs of male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and 
wild-type littermates at 2, 6, and 9 months of age.  Sagittal digital x-ray images of all 
genotypes appeared to have the same subchondral bone phenotype at 2 months old. Osteophyte 
formation (arrows) was visible in the posterior tibial plateau of Fgf2
ALLKO 
and Fgf2
LMWKO 
knees at 
6 and 9 months old. N=4-10/age group/genotype. 
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Figure 3.6.2. Analysis of cartilage integrity of male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and 
wild-type littermates. A, Safranin-O stained representative images of medial area of knees show 
similar histological appearances between all genotypes and their wild-type controls at 2 months 
of age. At 6 and 9 months of age Fgf2
ALLKO 
and Fgf2
LMWKO 
joints display fibrillation of articular 
cartilage (open arrowheads) and complete loss of cartilage (arrows) n=4-6/group. B, Mean 
medial tibial plateau OA score of  Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and WT at 6 months of 
age. Values are means ± SD, *p  <0.05, **P <0.01, n=5/group. C, H & E stained representative 
images of 6 month old Fgf2
LMWKO 
displays inflammation of the tendon and synovium (circle). 
N=3/group. Magnification=10X. 
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Figure 3.6.3. MicroCT imaging and histomorphometric analysis of subchondral bone of  
male Fgf2
HMWKO
, Fgf2LMWKO, and wild-type littermates at 6 months old. A, Three-
dimensional (3D) renderings reveal pitting and erosion (open arrowhead) and osteophyte 
formation (closed arrowhead) of Fgf2
LMWKO
 knees, while Fgf2
HMWKO
 and all WT knees maintain 
a smooth contour. High-resolution micro-computed tomography (μCT) 2D images of 
representative sections of all Fgf2
LMWKO
 samples show osteophyte formation of tibia (closed 
arrowhead) and thinning of femoral subchondral bone (dashed arrow) compared to the thicker 
femoral subchondral bone (arrow) of the WT littermate. Fgf2
LMWKO
 epiphyses display decreased 
trabecular thickness and number and increased trabecular spacing compared to WT and  
Fgf2
HMWKO
 epiphyses. N=3-7/group. B, Histomorphometric parameters of Fgf2
HMWKO
 and WT 
femoral and tibial epiphyses are similar. C, Histomorphometric parameters of Fgf2
LMWKO
 femoral 
and tibial epiphyses reveal decreases in BV/TV, Tb.Th, and Tb.N and an increase in Tb.Sp 
compared to WT. BV/TV, trabecular bone volume; Tb.Th, trabecular thickness Tb.Sp, trabecular 
separation; Tb.N, trabecular number. Values are the means ± SD. *P  <0.05, **P <0.01, ***P 
<0.001 N=5/group. 
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Figure 3.6.4. Matrix metalloproteinase 13 (MMP-13), a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS-5) expression in knees of 6 month old male 
Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type littermates. A, Representative 
immunohistochemical staining shows increased protein expression of MMP-13 along tibial 
articular cartilage of Fgf2
ALLKO
 and Fgf2
LMWKO
 (arrows) compared to WT littermates, while 
Fgf2
HMWKO
 and WT have similar MMP-13 expression. B, Representative images show increased 
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expression of ADAMTS-5 in the enlarged tendon and meniscus area of the medial tibia in both 
Fgf2
ALLKO
 and Fgf2
LMWKO
 (dashed arrows) compared to WT littermates, whereas Fgf2
HMWKO
 and 
WT have similar ADAMTS-5 expression of the same area. Magnification=10X, n=3/group. 
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Figure 3.6.5. Fgf2
HMWKO
 are protected from spontaneous (females) and mechanically-
induced (males) OA. A, 2 year old Fgf2
HMWKO
 and WT have similar subchondral bone 
phenotypes as determined by x-ray. Safranin-O staining of lateral side of joint shows loss of 
proteoglycan content (closed arrowhead) and fibrillation of cartilage (open arrowhead), 
compared to the more robust proteoglycan content of Fgf2
HMWKO 
samples. N=4-6/group. B, Mean 
total joint OA score of Fgf2
HMWKO
 is significantly lower than WT. Values are means ± SD, n=4-
5/group. C, Representative immunohistochemical staining shows decreased protein expression of 
ADAMTS-5 along tibial articular cartilage of  Fgf2
HMWKO
 (dashed arrow) compared to 
expression in WT littermates (arrows). D-E, 3D reconstructed images and μCT images of sagittal 
sections of right tibial-loaded knees (2 weeks after loading) of 21 month old Fgf2
HMWKO
 mice 
appear to have a similar appearance to the left contralateral control and both left and right knees 
of WT. Right tibial loaded knees of Fgf2
LMWKO
 mice show erosion of the tibial surface (arrow) 
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compared to the left contralateral control and all samples in D. Sagittal images display decreased 
femoral subchondral bone (dashed arrow) and increased trabecular spacing and decreased 
trabecular number in epiphyses compared to the contralateral control n=3-4/group. F, Safranin-O 
staining shows fissures (arrow) in cartilage of right tibial-loaded knees (2 weeks after loading) of 
21 months old WT littermates of Fgf2
HMWKO
 mice. OA score of right medial tibia of WT 
littermates of Fgf2
HMWKO
 mice was significantly higher than all others. G, Right tibial loaded 
knees of 12 week old  Fgf2
LMWKO
 mice (2 weeks after loading) show fraying (arrow)  and a 
significantly higher OA score than controls. Values are means ± SD, p <0.05**p <0.01, ***p  
<0.001. 
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Figure 3.6.6. Gene expression of joints of 2 month old male Fgf2
ALLKO
, Fgf2
HMWKO
, 
Fgf2
LMWKO
, and wild-type littermates. A, qPCR analysis of genes with modulated expression in 
both Fgf2
ALLKO
 and Fgf2
LMWKO 
samples. B, qPCR analysis of genes with increased expression 
only Fgf2
ALLKO 
samples. C, qPCR analysis of genes with increased expression in only Fgf2
LMWKO 
samples. Values are the means ± SD. *P  <0.05**P <0.01, ***P  <0.001, n=6-8/group. 
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Figure 3.6.7. FGF2 protein expression in 2 and 6 month old male Fgf2
ALLKO
, Fgf2
HMWKO
, 
Fgf2
LMWKO
, and wild-type littermates. A, Immunohistochemical staining of tibial articular 
cartilage shows no FGF2 expression in 2 month old Fgf2
ALLKO
 tissue (dashed arrows) compared 
to WT. Fgf2
LMWKO 
cartilage had increased FGF2 expression (arrow) compared to WT. B, 6 
month old femoral articular cartilage shows no FGF2 expression in Fgf2
ALLKO
 cartilage (dashed 
arrow) compared to WT. FGF2 expression was increased in Fgf2
LMWKO 
cartilage (arrow) 
compared to WT cartilage. Magnification=10X. C, Higher magnification of 6 months old joints 
shows localization of FGF2 isoforms. In WT and Fgf2
HMWKO
 cartilage, FGF2 is expressed in 
both the nucleus and cytoplasm of chondrocytes. FGF2 is only expressed in the nuclei Fgf2
LMWKO 
cartilage. No FGF2 expression was detected in Fgf2
ALLKO
 tissue. Magnification =40X, 
n=3/group. 
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Figure 3.6.8. FGF23 protein expression in 2 and 6 months old male Fgf2
ALLKO
, Fgf2
HMWKO
, 
Fgf2
LMWKO
, and wild-type littermates. A, Representative immunohistochemical staining shows 
enhanced protein expression of FGF23 in tibial articular cartilage of Fgf2
LMWKO
 (arrows) 
compared to WT littermates, while Fgf2
ALLKO
 and Fgf2
HMWKO
 had similar FGF23 expression to 
their WT littermates at 2 months of age. B, Both Fgf2
LMWKO 
and Fgf2
ALLKO
 had increased FGF23 
staining in articular cartilage compared to WT, and Fgf2
HMWKO
 had similar FGF23 expression to 
their WT at 6 months of age. Magnification=10X, n=3/group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
Figure 3.6.9. FGFR1, FGFR3, and ERK protein expression in 6 months old male Fgf2
ALLKO
, 
Fgf2
HMWKO
, Fgf2LMWKO, and wild-type littermates. A, Immunohistochemical staining shows 
total FGFR1 expression was more robust in tibial articular cartilage of Fgf2
ALLKO
 (arrows). 
FGFR1 was also increased in the joints of Fgf2
LMWKO
, particularly in the enlarged meniscus and 
developing osteophytes areas (arrows). Fgf2
HMWKO
 had similar FGFR1 expression to the WT. B, 
phospho-FGFR1 was present in tibial cartilage of Fgf2
ALLKO
 (arrow). Fgf2
LMWKO
 cartilage had 
increased phopho-FGFR1 expression (arrows). C, phospho-FGFR3 expression was decreased in 
Fgf2
ALLKO
 and Fgf2
LMWKO 
femoral articular cartilage (dashed arrows) compared to WT, while 
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Fgf2
HMWKO
 had increased FGFR3 staining (arrow). D, phospho-ERK expression was only 
detected in Fgf2
LMWKO
 cartilage (arrows). Magnification=10X, n=3/group. 
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Table 3.6.1. Primers used in qRT-PCR. 
 
Gene Forward Reverse 
Actb 5’-atggctggggtgttgaaggt-3’ 5’-atctggcaccacaccttctacaa-3’ 
Elk1 5’-ttggaggcctgtctggaggctgaa-3’ 5’-agctcttccgatttcaggtttggg-3’ 
Adamts5 5’-cctgcccacccaatggtaaa-3’ 5’-ccacatagtagcctgtgccc-3’ 
Col10a1 5’-gggaccccaaggacctaaag-3’ 5’-gcccaactagacctatctcacct-3’ 
Vegf 5’-gcacatagagagaatgagcttcc-3’ 5’-ctccgctctgaacaaggct-3’ 
Fgf2 5’-gtcacggaaatactccagttggt-3’ 5’-cccgttttggatccgagttt-3’ 
Fgf23 5’-acttgtcgcagaagcatc-3’ 5’-gtgggcgaacagtgtagaa-3’ 
Fgfr1 5’-gactgctggagttaatacca-3’ 5’-ctggtctctcttccagggct-3’ 
Fgfr3 
 
Sox9 
 
Bmp4 
 
Igf1 
 
Il1b 
 
Hif1a 
 
Bcl2 
 
Bax 
5’-gttctctctttgtagactgc-3’ 
 
5’-agtacccgcatctgcacaac-3’ 
 
5’-gccggagggccaagcgtagccctaag-3’ 
 
5’-gtgagccaaagacacaccca-3’ 
 
5’-gcaactgttcctgaactcaact-3’ 
 
5’-caagatctcggcgaagcaa-3’ 
 
5’-gagagcgtcaacagggagatg-3’ 
 
5’-tgaagacaggggcctttttg-3’ 
5’-agtacctggcagcacca-3’ 
 
5’-acgaagggtctcttctcgct-3’ 
 
5’-ctgcctgatctcagcggcacccacatc-3’ 
 
5’-acctctgattttccgagttgc-3’ 
 
5’-atcttttggggtccgtcaact-3’ 
 
5’-ggtgagcctcataacagaagcttt-3’ 
 
5’-ccagcctccgttatcctgga-3’ 
 
5’-aattcgccggagacactcg-3’ 
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Supplemental Figure 3.6.1. Fgf2
ALLKO 
male develop spontaneous and mechanically-induced 
OA. A, H & E stained representative images of 6 months old Fgf2
ALLKO
 samples show loss of 
articular cartilage and no inflammation. N=3/group. B, Histomorphometric parameters of 
Fgf2
ALL KO
 femoral and tibial epiphyses reveal decreases in BV/TV, Tb.Th, and Tb.N and an 
increase in Tb.Sp compared to WT. Values are the means ± SD. *P  <0.05, **P <0.01, ***P 
<0.001, N=5/group. C, Right tibial loaded knees of Fgf2
ALL KO
 mice have pitting of the tibial 
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surface (arrow) compared to the left contralateral control and WT. Sagittal images display 
decreased femoral subchondral bone (dashed arrow) and increased trabecular spacing and 
decreased trabecular number in femoral epiphyses compared to the contralateral control and WT. 
N=4-5/group. 
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Supplemental Figure 3.6.2. Histomorphometric analysis of subchondral bone of 2 months 
old male Fgf2
ALLKO
, Fgf2
HMWKO
, Fgf2LMWKO, and wild-type littermates. A-C,  
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Histomorphometric parameters of femoral and tibial epiphyses are similar between Fgf2
ALLKO
 
Fgf2
HMWKO
, Fgf2LMWKO, and their respective WT littermates. Values are the means ± SD, 
n=3/group. 
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4.1 Abstract 
Although humans with X-linked hypophosphatemia (XLH) and the Hyp mouse, a murine 
homologue of XLH, are known to develop severe degenerative joint disease, the exact 
mechanism which drives the osteoarthritic (OA) phenotype remains unclear. Mice that 
overexpress the high molecular weight FGF2 isoforms (HMWTg mice) phenocopy both XLH 
and Hyp, including OA with increased fibroblast growth factor 23 (FGF23) production in bone 
and serum.  Since HMWTg cartilage also has increased FGF23 expression and there is crosstalk 
between FGF23-Wnt/β-catenin signaling, the purpose of this study was to determine if OA 
observed in HMWTg mice is due to FGF23 mediated-canonical Wnt signaling in chondrocytes 
given that both pathways are implicated in OA pathogenesis. HMWTg OA joints had decreased 
Dkk1, Sost, and Lrp6 expression with increased Wnt5a, Wnt7b, Lrp5, Axin2, phospho-GSK3, 
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Lef1, and nuclear β-catenin as indicated by immunohistochemistry or qPCR analysis. 
Chondrocytes isolated from HMWTg mice had enhanced alcian blue and alkaline phosphatase 
staining and increased FGF23, Adamts5, Il-1β, Wnt7b, Wnt16, and Wisp1 gene expression and 
phospho-GSK3 protein expression as indicated by Western blot compared to chondrocytes of 
Vector control and chondrocytes harvested from mice overexpressing the low molecular weight 
isoform, which were shown to be protected from OA. Canonical Wnt-inhibitor treatment rescued 
some of those parameters in HMWTg chondrocytes, seemingly delaying the initial accelerated 
chondrogenic differentiation. Neutralizing FGF23Ab treatment was able to partly ameliorate OA  
abnormalities of the subchondral bone and reduce expression of degradative/hypertrophic 
chondrogenic markers in HMWTg mouse joints in vivo. These results demonstrate that 
osteoarthropathy of HMWTg is at least partially due to FGF23 modulated Wnt/β-catenin 
signaling in chondrocytes. 
 
 
4.2 Introduction 
Osteoarthritis (OA) is a chronic disabling joint disease, mainly of the knee, which affects 
millions of people and disturbs all areas of the joint, including the subchondral bone, meniscus, 
and synovium, but is primarily characterized by the degradation of articular cartilage (1,6). This 
cartilage is comprised of unique chondrocytes which synthesize extracellular matrix (ECM) 
components and a variety of catabolic and anabolic factors in order to maintain healthy cartilage 
homeostasis. When this balance is perturbed and various biochemical pathways are activated 
within chondrocytes, there is a breakdown of the ECM by degradative enzymes, inflammation 
occurs, and chondrocytes undergo dedifferentiation and hypertrophy, ultimately leading to OA 
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(6,7). Unfortunately, the molecular mechanisms that cause OA are not fully understood and there 
is a crucial need to further study these biochemical pathways that contribute to the disease in 
order to identify therapeutic targets to effectively treat OA.  
 The Wnt signaling pathway has been a well-recognized regulator in not only skeletal and 
embryonic development, but in cartilage homeostasis and the pathophysiology of OA (48,49).  
Though there have been contradictory findings regarding either the activation or inhibition of 
Wnt signaling on joint homeostasis (51,52), there are numerous studies that suggest that cartilage 
degradation is a result of excessive canonical Wnt signaling, which is initiated by binding to low-
density lipoprotein receptor (LRP) 5 or 6, leading to stabilization and nuclear translocation of β-
catenin, and transcription of its target genes, such as Wnt-induced signaling protein-1 (WISP1), 
which has been shown to be increased OA cartilage of mice (52-56). Specifically, Wnt7b, an 
exclusively canonical ligand, was found to be upregulated in human OA cartilage (55) and 
Wnt16 and nuclear -catenin expression were increased in OA cartilage with a decreased 
expression of Wnt inhibitors (54,56). Also, human and mouse OA cartilage was found to have an 
upregulation of LRP5, and mice lacking Lrp5 were protected from experimental OA (53). Thus, 
aberrant canonical Wnt/-catenin signaling negatively impacts cartilage. 
Interestingly, fibroblast growth factor 23 (FGF23) is upregulated in human OA 
chondrocytes (45) and exogenous expression of FGF23 stimulates hypertrophy and increases 
FGFR1 production in chondrocytes (46,47). FGF signaling has been found to augment nuclear -
catenin levels by inactivating glycogen synthase kinase (GSK) 3 (60), and Wnt/-catenin 
activity was shown to stimulate FGF23 promoter activity in osteoblasts (61). Together these 
studies imply that FGF23 and canonical Wnt signaling cooperatively may be contributing to OA. 
We previously published that mice which overexpress the high molecular weight isoforms of 
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FGF2 (HMWTg mice) in osteoblastic lineage cells spontaneously develop signs of OA as early 
as 2 months of age, including increased degradative enzymes, a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTS) and matrix metalloproteinases (MMPs), FGF23, and 
FGFR1 expression in the cartilage, while mice that overexpress the low molecular weight 
isoform (LMWTg) were protected from OA (83). HMWTg mice mimic subjects that have X-
linked hypophosphatemia (XLH) in that they have decreased bone mineral density, rickets, 
osteomalacia, hypophosphatemia, osteoarthropathy, and elevated levels of FGF23, which are 
traits in which the HMWTg mice phenocopy Hyp mice (38), a murine homologue of XLH. 
Additionally, Wnt signaling components are enhanced in Hyp mice (61, 62). The aim of this 
study is determine if the OA phenotype observed in HMWTg mice is due to increased FGF23 
and canonical Wnt signaling in chondrocytes.  
 
4.3 Materials and Methods 
 
4.3.1. Experimental animals 
All animal protocols were approved by the UConn Health Institute of Animal Care and Use 
Committee. We have previously described in detail the generation of HMWTg and Vector 
(control) transgenic mice (38). HMWTg mice overexpress human HMW FGF2 isoforms in bone, 
using the Col3.6-HMW-IRES-green fluorescent protein-sapphire (GFPsaph) construct in which a 
CAT fragment of the previously generated construct, Col3.6-CAT-IRS-GFPsaph, was replaced 
with HMW isoforms of human FGF2 cDNA. Thus, allowing HMW and GFPsaph to be 
concurrently overexpressed from a single bicistronic mRNA. Vector mice overexpress the 
transgene cassette, Col3.6-IRES/GFPsaph, without the additional FGF2 coding sequences. 
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Col3.6-CAT-IRES-GFPsaph or Col3.6-IRES/GFPsaph construct inserts were released via 
digestion by AseI and AflII. Microinjections in the pronuclei of fertilized oocytes were 
performed at the Gene Targeting & Transgenic Facility at UCONN Health. To establish the 
individual transgenic mouse lines founder mice of the F2 (FVBN) strain were mated with wild-
type mice. Mice that overexpress the human LMW isoform FGF2 were generated using a similar 
method as described above (34). In vivo studies used male homozygous Vector and HMWTg 
without antibody treatment and female homozygous Vector and HMWTg mice for antibody 
treatment studies. Both male and female 5 day old pups of Vector, HMWTg, and LMWTg were 
used for all in vitro studies. 
 
4.3.2. Histology 
Following dissection 2-month-old murine knees were fixed in 4% paraformaldehyde, decalcified 
using a 14% EDTA solution, processed for paraffin embedding in a frontal orientation, and cut 
into 7-μm alternate sections. The ImmunoCruz ABC Staining System (Santa Cruz 
Biotechnology) was used for all immunohistochemical staining. After sections were 
deparaffinized and rehydrated, antigen retrieval was done by incubating sections with 10mM 
sodium citrate buffer for 10 minutes at 95°C. To reduce endogenous target, slides were blocked 
with 3% hydrogen peroxide in water for 15 minutes, then blocked for 1 hour with 10% serum, 
and incubated with primary antibodies in blocking buffer at 4°C overnight. The following 
primary antibodies were used (details can be found in Table 1): goat anti-SOST (R & D 
Systems), rabbit anti-pLRP6(Bioss), rabbit anti-pLRP5 (Abcam), goat anti-WNT5A (R & D 
Systems), rabbit anti-WNT7B (GeneTex), rabbit anti-pGSK3β (Abcam), rabbit anti-LEF1 
(Sigma-Adlrich), rabbit anti-non-phospho β-catenin (Cell Signaling) rabbit anti-MMP13 (abcam), 
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and goat anti-MMP19 (Santa Cruz). A negative control slide was used each time, which was 
incubated overnight with only blocking serum. Sections were then washed and incubated with 
the appropriate 1:200 biotinylated secondary antibody for 30 minutes. Finally, slides were 
washed, developed with DAB Peroxidase Substrate kit (Vector Laboratories), and counterstained 
with Harris hematoxylin. 
 
4.3.3. RNA isolation and real time PCR 
For in vivo studies, following removal of skin and bulk muscle of the knee, total RNA was 
extracted from the entire joint which included all components above the growth plate using 
TRIzol reagent (Invitrogen) (34). For real-time quantitative RT-PCR (qRT-PCR) analysis, the 
RNA to cDNA EcoDry Premix kit (Clontech Inc., A Takara Bio Company) was used to reverse-
transcribe the RNA to cDNA . iTaq
TM
 Universal SYBR Green Supermix (Bio-Rad, CA, USA) 
and a Bio-Rad MyiQ
TM
 instrument (BIO-RAD Laboratories Inc. Hercules, CA) were utilized for 
qPCR. The relative change in mRNA level was normalized to the mRNA level of Beta-actin (β-
actin), which served as an internal reference for each sample. For in vitro studies, RNA was 
extracted from culture plates using TRIzol reagent and qPCR performed as described above. 
Additionally, mRNA was normalized to the β-actin mRNA level and expressed as the fold-
change relative to the appropriate Vector group. Table 2 lists the primers, synthesized by IDT 
(Integrated DNA Technologies, Inc., CA), for the genes of interest. 
 
4.3.4. Radiology and microcomputed tomography analysis 
Digital x-rays of excised knee joints taken in the frontal plane were captured under consistent 
conditions (26 kV at 6-s exposure) using a SYSTEM MX 20 from Faxitron X-ray Corporation 
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(Faxitron X-ray Corp.). Imaging of knee architecture was performed using ex vivo micro-
computed tomography (μCT40, ScanCo Medical AG, Bassersdorf, Switzerland). The following 
morphometric parameters of the region of subchondral trabecular bone of the epiphysis in the 
femur and tibia were analyzed by 3-dimensional (3D) microcomputed tomography (μCT): bone 
volume/tissue volume (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), and 
trabecular number (Tb.N). 
 
4.3.5. FGF23 neutralizing antibody treatment 
Female HMWTg mice were treated with a rat anti-rat FGF23 neutralizing antibody (FGF23Ab) 
(Amgen Inc.), at a dose of 10mg/kg body weight or control IgG (rat-anti-NGFPb-3F8-raIgG2a) 
by intraperitoneal injection (ip) twice a week, beginning at 8 weeks of age for 6 weeks. This 
dosage was previously established in our lab in a pilot experiment. Initially, Vector mice were 
treated with control IgG (Vehicle) only, but an additional experiment that included Vector mice 
treated with FGF23Ab (as an added control group) or control IgG treatment was performed by 
initiating injections twice a week at 3 weeks of age for 6 weeks and combined into the study. 
Mice were euthanized by CO2 and knees were collected. Sections were obtained by methods 
described and Safranin-O staining using 0.1% aqueous Safranin-O with 0.02% aqueous Fast 
Green and Weigert’s Iron Hematoxylin counterstain was performed. 
 
4.3.6. Chondrocyte culture 
Chondrocytes were dissected from approximately 5 day old male and female Vector, HMWTg, 
and LMWTg pups from the femoral head, femoral condyles, and tibial plateau using a dissecting 
Zeiss microscope. Cartilage was collected in high-glucose DMEM (Life Technologies) and 
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digested in .25% trypsin (Life Technologies) for 30 minutes and then incubated with 500 U/ml of 
collagenase type II (Worthington Biochemical Corporation) for 3 hours at 37°C. Cells were 
collected and cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin 
(P/S) (Life Technologies) (95) .The cells were plated at a density of 100,000 cells/cm
2
, incubated 
for 7 days with media changes every other day, fixed, and stained with Alcian Blue (3% in acetic 
acid, pH 2.5) (Poly Scientific) or Vector Blue Alkaline Phosphatase Substrate (Vector 
Laboratories). For inhibitor experiments, chondrocyte culture medium was supplemented with 
10µM IWR-1 endo (Santa Cruz) or .1% dimethyl sulfoxide (DMSO) on day 5 when cells are 
approximately 70% confluent for 48 hours.  
 
4.3.7. Western blot analysis 
Protein was extracted from primary articular chondrocytes on day 7 in culture using 1× 
radioimmune precipitation buffer (Cell Signaling Technology, Inc.), and protein concentration 
was assayed with BCA protein assay reagent (Thermo Scientific). Following SDS-
polyacrylamide gel electrophoresis on mini protean gels (Bio-Rad Laboratories), proteins were 
transferred to Immuno-Blot PVD membranes (Bio-Rad Laboratories). Membranes were probed 
using antibodies including a rabbit polyclonal anti-phospho-Gsk3β (Ser9; 9336, Cell Signaling), 
a rabbit monoclonal anti-Gsk3β (9315; Cell Signaling), a rabbit polyclonal anti-AXIN2 
(SAB3500619; Sigma Aldrich), a rabbit monoclonal anti-non-phospho (active) β-
catenin(Ser
33/37
/Thr
31, 8814; Cell Signaling), a rabbit polyclonal β-catenin (sc7199; Santa Cruz),  
a  monoclonal β-actin (sc47778; Santa Cruz) and a goat secondary antibody against rabbit (7074; 
Cell Signaling). Immunoreactive bands were visualized using Supersignal West Dura Extended 
Duration Substrate (Thermo Scientific) and autoradiography film (Lab Scientific Inc) in 
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accordance with the manufacturer’s instructions. ImageJ was used to densitometrically quantify 
band densities.  
 
4.3.8. Statistical analysis 
Results are presented as means ± S.D. Student’s t-test was used to analyze differences between 
groups. Differences were considered significant at p values less than 0.05. 
 
4.4 Results 
 
4.4.1. Expression of Wnt signaling components in Vector and HMWTg joints 
Previously, we have shown that HMWTg mice develop osteoarthropathy as early as 2 months of 
age and in order to determine if Wnt signaling may be contributing to this phenotype, we 
examined 2-month-old male Vector and HMWTg knees for protein and gene expression of 
components of the Wnt signaling pathway. Sclerostin (SOST), a Wnt inhibitor, was not present 
in HMWTg knees, however, Vector mice had SOST expression in the subchondral bone. 
Phosphorylated LRP6 receptor protein was decreased in HMWTg articular cartilage, compared 
to Vector cartilage, yet phosphorylated LRP5 was strongly expressed in HMWTg cartilage 
compared to Vector. Ligands,WNT5A and WNT7B, were greatly increased in HMWTg cartilage 
compared to Vector. Also, phosphorylated inactive GSK3β and Lymphoid Enhancer Binding 
Factor 1 (LEF1), both downstream components of canonical Wnt signaling, had strong 
expression in HMWTg compared to Vector articular cartilage (Fig. 1A). To determine if 
specifically canonical Wnt signaling, in which β-catenin does not become degraded, was 
upregulated in HMWTg joints, we examined non-phosphorylated β-catenin by 
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immunohistochemistry and expression was only present in HMWTg cartilage and not in Vector 
knees (Fig. 1B). We then examined gene expression in whole joints from 2-month-old Vector 
and HMWTg mice and similarly found that the Wnt inhibitors Sost and Dickkopf WNT 
Signaling Pathway Inhibitor (Dkk1), and receptor Lrp6 mRNA levels were significantly 
decreased in HMWTg compared to Vector. Also, Wnt5a, Axin2, and Lef1 gene expression was 
significantly increased in HMWTg joints compared to the Vector control (Fig. 1C). 
 
4.4.2. Characterization of immature murine articular chondrocytes (iMACs) from Vector, 
HMWTg, and LMWTg mice 
To be able to study more directly how the chondrocyte phenotype and Wnt/β-catenin signaling is 
modulated in Vector, HMWTg, and LMWTg mice, we microsurgically dissected articular 
cartilage from postnatal mice (one litter/genotype/experiment) and studied in vitro in monolayer. 
On day 7 in culture, chondrocytes reached confluence and were fixed and stained for alcian blue. 
From four independent experiments chondrocytes from LMWTg consistently had slightly less 
blue staining, whereas, HMWTg chondrocytes had more robust staining, indicating increased 
glycosaminoglycan content compared to Vector or LMWTg (Fig. 2A). Similarly, alkaline 
phosphatase staining was markedly less in LMWTg chondrocytes and staining in HMWTg 
chondrocytes was highly increased, indicating enhanced hypertrophic differentiation (Fig. 2A). 
Next, RNA was isolated from cultures on day 7 and qPCR analysis was used to determine 
expression levels of genes involved in FGF and Wnt signaling and OA pathogenesis. Of 
importance, Fgf23, Adamts5, Interleukin 1 beta (Il1-β), Wnt7b, Wnt16, and Wisp1 were 
significantly increased in HMWTg chondrocytes. Also, FGF23, Il1-β, and Wnt7b were 
significantly decreased in LMWTg chondrocytes (Fig. 2B). Table 3 lists any genes that had 
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significant difference in mRNA level between genotypes and it was determined that HMW 
chondrocytes had increased Fgf18 levels but not as elevated as LMW chondrocytes. Also, 
FGFR3 expression was decreased in HMW chondrocytes but FGFR3c was increased in HMW 
compared to Vector. Degradative enzyme, Mmp9, expression level was significantly increased in 
HMW compared to LMW. Transcription factors Sex determining region Y box 9 (Sox9), ColX, 
Indian hedgehog (Ihh), and Sclerostin domain containing 1 (Sostdc1) expression was 
significantly less in LMW compared to Vector. While Col1 levels were increased in HMW, NK3 
Homeobox 2 (Nkx3.2) and Wnt10b were decreased compared to Vector. To further determine if 
Wnt signaling is modulated in these chondrocytes we examined phospho-GSK3β protein 
expression by Western blot. From three independent experiments it was determined that 
HMWTg had a statistically significant increase in phospho-GSK3β (Fig. 2C), indicating that 
there is more inactive GSK3β, allowing less degradation of β-catenin and subsequent enhanced 
transcription of β-catenin target genes.  
 
4.4.3. Inhibition of Wnt/β-catenin on chondrocyte homeostasis 
In order to determine if canonical Wnt signaling is contributing to the enhanced chondrocyte 
differentiation and hypertrophy and OA in HMWTg cells, we treated cultures with IWR-1, a 
potent Wnt inhibitor that stabilizes Axin2, a member of the β-catenin destruction complex, 
ultimately leading to the degradation of β-catenin (96). This stabilization of Axin2 was 
confirmed by increased Axin2 protein expression by Western blot in Vector, HMWTg, and 
LMWTg groups compared to their Vehicle-treated controls (Fig. 3A). Consequently, active β-
catenin versus total β-catenin was decreased after IWR-1 treatment for all genotypes as 
determined by Western blot and the initial increase in active β-catenin in HMWTg Vehicle-
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treated compared to Vector and LMWTg was observed (Fig. 3A). IWR-1 treatment of 
chondrocytes caused a decrease in both alcian blue and alkaline phosphatase staining in HMWTg 
cultures, which appeared similar to that of Vector and LMWTg Vehicle-treated groups. 
However, IWR treatment did not affect the staining in Vector or LMWTg cultures (Fig. 3B). 
Furthermore, IWR-1 markedly reduced mRNA expression of the initially high Fgf23 expression 
in HMWTg chondrocytes, yet somewhat increased expression in Vector and LMWTg. Adamts5 
elevated expression was rescued in HMWTg after IWR-1 treatment. Though Axin2 gene 
expression was significantly increased in HMWTg Vehicle-treated chondrocytes compared to the 
Vector Vehicle-treated, mRNA levels were not significantly altered following IWR-1 treatment 
compared to each group’s Vehicle-treated controls. qPCR also showed enhanced Wnt7b 
expression in HMWTg, which was reduced after IWR-1 treatment (Fig. 3C). 
 
4.4.4. Effects of long-term FGF23Ab treatment on joint homeostasis in Vector and HMWTg 
Since HMWTg knees and chondrocytes have an OA phenotype and increased FGF23 expression, 
and FGF23 has been found to promote chondrocyte hypertrophy and differentiation (47), we 
assessed whether neutralization of FGF23 could rescue the OA phenotype in HMWTg mice. As 
shown by digital radiography the flattened tibial plateau and narrowing of the joint space in the 
HMWTg Vehicle-treated group was rescued following FGF23Ab treatment (Fig. 4A). 3D 
renderings show abnormal contour and erosion of the subchondral surface in the HMWTg 
Vehicle-treated group, while FGF23Ab treatment resulted in a phenotype resembling that of the 
Vector groups (Fig. 4B). Sagittal microCT images reveal irregular shape and thinning of the 
subchondral bone with decreased trabeculae number and thickness within the epiphyses of 
HMWTg Vehicle-treated knees, which was rescued following FGF23Ab injections (Fig. 4B). 
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Specifically, HMWTg Vehicle-treated femoral epiphyses had altered trabecular architecture 
indicative of early OA and 3D morphometric parameters calculated from microCT results of the 
epiphyses indicated increased BV/TV, trabecular thickness and number, and decreased trabecular 
spacing, compared to Vector Vehicle-treated epiphyses, which were partially normalized with 
FGF23Ab treatment (Fig. 4C). Finally, increased hypertrophic OA gene markers found in 
mRNA from HMWTg Vehicle-treated joints showed rescue after FGF23Ab treatment, which 
included ColX, Mmp13, and Mmp9 (Fig. 4D). Protein expression of MMP13 and MMP9 was 
strongly expressed in HMWTg Vehicle-treated cartilage, but not present in either Vector group 
or HMWTg FGF23Ab-treated mice (Fig. 4F&G). Articular cartilage thickness was decreased in 
HMWTg Vehicle-treated mice, similar to what was observed in our initial study (17) and was 
then restored to the cartilage thickness of Vector mice in the HMWTg FGF23Ab-treated group 
(Fig. 4E). 
 
4.5 Discussion 
 This study examined modulation of FGF23 and canonical Wnt signaling in chondrocytes 
obtained from mice that overexpress the high molecular weight isoforms of FGF2 and develop 
OA. We found the following: (i) Joints of HMWTg mice, which have elevated FGF23 
expression, had decreased Sost, Dkk1, and Lrp6 expression and increased Wnt7b, Wnt5a, Lrp5, 
Axin2, Gsk3β, Lef1, and nuclear β-catenin levels. (ii) Chondrocytes of HMWTg mice had 
accelerated differentiation and increased Fgf23, Adamts5, Il-1β, Wnt7b, Wnt16, Wisp1, and 
phospho-Gsk3β. (iii) Inhibition of canonical Wnt signaling rescued hypertrophy and Fgf23, 
Adamts5, and Wnt7b levels in HMWTg chondrocytes. (iv) The OA phenotype in HMWTg mice 
can be partially rescued by neutralizing FGF23Ab treatment in vivo. Collectively, this data 
98 
 
suggests that FGF23 modulates Wnt/β-catenin signaling promoting chondrocyte differentiation, 
resulting in OA (Fig. 5). 
 Disruption of cartilage homeostasis is a primary reason of OA pathogenesis and is 
initiated by varying physical or genetic factors, leading to an imbalance of anabolic and catabolic 
factors, resulting in modulation of various biochemical pathways (7). Although we have 
previously published that HMWTg mice, phenocopy both Hyp mouse and XLH, spontaneously 
develop degenerative joint disease, the molecular mechanism driving this OA phenotype was 
unclear (83), but in this study we show for the first time that FGF23 is a catabolic regulator of 
Wnt/β-catenin signaling-mediated OA cartilage destruction. In vivo we observed increased 
FGF23 and FGFR1 expression in HMWTg cartilage (83) and it is well established that FGF23 
stimulates hypertrophy, and signaling through FGFR1 leads to a cascade of events that are 
catabolic in articular chondrocytes (25). Also, FGFR signaling has been shown to increase 
Wnt/β-catenin signaling in chondrocytes (59). Though Wnt signaling can have differing effects 
on cartilage homeostasis (51,52), our findings are consistent with its negative role. We found that 
inhibitors, Sost and Dkk1, were decreased in HMWTg joints, essentially allowing activation of 
the Wnt pathway, and similarly it was found that increased Sost and Dkk1 levels protect against 
cartilage degradation in OA in mice (57,58). Interestingly, we observed an increase in LRP5 with 
a decrease in LRP6 in HMWTg, which further strengthens the argument that these receptors can 
have distinct functions, and that LRP5 (but not LRP6) is essential for Wnt-induced cartilage 
destruction by regulating production of MMPs (53), as we have also shown increased MMPs 
expression in vivo and in vitro.  
While aberrant noncanonical Wnt signaling can contribute to OA (49,50) and we 
observed increased Wnt5a expression in HMWTg, which is most often associated with the 
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noncanonical pathway, there is evidence that suggests that Wnt5a activates the canonical 
pathway in the presence of LRP5 (97), which was also increased in our study. Furthermore, we 
observed increased Wnt7b expression in HMWTg chondrocytes, which is an exclusively 
canonical ligand (55), increased inactivation of Gsk3β, increased LEF1, Wisp1, and nuclear β-
catenin, which indicates that β-catenin is stabilized and translocated to the nucleus, which is due 
to enhanced canonical signaling.  
Since various areas within an osteoarthritic joint contribute to the disease, it is of great 
importance that we were able to identify the articular chondrocyte as the component of the knee 
that may be responsible for the pathogenesis of OA observed in HMWTg mice. Even though in 
the Hyp mouse (which has increased Wnt signaling in varying tissues (61,62)) it was determined 
that cellular changes occur within articular cartilage that contribute to the osteoarthropathy, these 
mice and humans with XLH also develop OA-like changes in the subchondral bone and tendons 
(44) so it was unclear what tissue was driving the phenotype. Isolating articular chondrocytes 
from pups that were only 5 days old and growing for just 7 days in undifferentiating media 
mimicked the in vivo results of HMWTg cartilage, which included increased FGF23/catabolic 
factor expression, mineralization, and chondrogenic hypertrophy (83). Firstly, alcian blue and 
alkaline phosphatase (mineralization) staining was strongest in HMWTg and lowest in LMWTg 
cultures, indicating that HMWTg chondrocytes have accelerated chondrogenic differentiation. 
Col1 was statistically significantly increased in HMWTg cultures and ColX was decreased in 
LMWTg cultures, which are markers for fully differentiated chondrocytes (98). Also, LMWTg 
cultures had a significant reduction in Sox 9, which acts further at each stage in chondrogenic 
differentiation (99) and  Ihh, which simulates chondrogenic cell differentiation (100), while 
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HMWTg cultures had a decrease in Nkx3.2, which has been found to decrease as chondrocytes 
mature and become more hypertrophic (101). 
Although FGFR3c was increased in HMWTg cultures, total FGFR3 was significantly 
decreased, which is the primary receptor of FGF18 (which was greatly increased in LMWTg) 
and downstream signaling promotes anabolic activity in chondrocytes (27). Just as we had 
previously observed in vivo, HMWTg chondrocytes are unable to maintain their normally 
quiescent nature resulting in rapid chondrogenesis, whereas, LMWTg chondrocytes appear to 
have slower differentiation potential resulting in protection from OA. Further studies will be 
needed to fully elucidate the mechanism by which the LMW FGF2 isoform confers a 
chondroprotective effect. 
The OA phenotype in HMWTg but not LMWTg chondrocytes is due to enhanced 
canonical Wnt signaling mediated by FGF23 since in addition to increased FGF23 mRNA levels, 
HMWTg chondrocytes had increased expression of other components of the Wnt/β-catenin 
signaling pathway. Once the cells were treated with a canonical Wnt inhibitor, IWR-1, which 
stabilizes Axin2 allowing more degradation of cytoplasmic β-catenin, the hypertrophic 
phenotype was rescued in HMWTg chondrocytes. Also, Adamts5 expression was decreased to 
levels found in Vector or LMWTg chondrocytes following treatment in HMWTg cultures. 
Interestingly, FGF23 and Wnt7b elevated expression in HMWTg chondrocytes was markedly 
reduced after IWR-1 treatment. This decrease in FGF23 expression may be due to inhibition of 
active  β-catenin, which has been found to enhance FGF23 promoter activity (61). Similarly, in 
the presence of higher levels of FGF23 we showed there was increased Wnt7b expression, so if 
FGF23 is unable to be transcribed we would expect to see a decrease in Wnt7 levels. However, 
future studies are necessary to determine how FGF23 signaling regulates Wnt7b expression.   
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Additionally, this study identified a potential therapeutic approach to partially rescue 
osteoarthropathy in HMWTg mice by long-term treatment with a neutralizing FGF23Ab, which 
has previously been reported to ameliorate rickets, osteomalacia, and hypophosphatemia in the 
Hyp mouse (102) and human subjects with XLH (103). This is a novel finding in that there are 
no disease modifying drugs to treat degenerative joint disease and the effect of FGF23Ab 
treatment on the OA phenotype in the earlier studies was not examined (102,103). Specifically, 
the microarchitecture of the subchondral bone was able to be restored to that of the Vector 
control after FGF23Ab treatment. Notably, ColX and MMPs expression was reduced in HMWTg 
+ FGF23Ab treated knees, which indicates that neutralizing FGF23 is restoring chondrocyte 
function, since these degradative/hypertrophic markers are expressed by osteoarthritic articular 
cartilage, as was observed by immunohistochemistry in the HMWTg + Vector group. The rescue 
of cartilage thickness also indicates the impact of the antibody on chondrocytes. 
Herein we provide evidence suggesting that FGF23 catabolically influences OA 
pathophysiology through canonical Wnt/β-catenin signaling in chondrocytes. These results 
provide new insight into the role of FGF23 in the pathogenesis of cartilage degradation in the 
context of XLH and identify Wnt/β-catenin FGF23-mediated signaling as a candidate pathway to 
be targeted in the treatment or prevention of OA.  
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4.6 Figures 
 
 
Figure 4.6.1. Expression of components of the Wnt pathway in knees of 2-month-old male 
Vector and HMWTg mice. A, Representative immunohistochemical staining shows no protein 
expression of SOST in the subchondral bone of HMWTg compared to Vector (arrowheads) and 
decreased phospho-LRP6 expression in articular cartilage (dashed arrows). Arrows indicate 
increased expression of phospho-LRP5, WNT5A, WNT7B, phospho-GSK3, and LEF1 in 
HMWTg cartilage compared to Vector. Magnification=10X, n=3/group. B, Representative 
images show evidence of active -catenin protein expression in HMWTg cartilage (arrows). 
Magnification=20X, n=3/group. C, qPCR analysis shows decreased Sost, Dkk1, and Lrp6 and 
increased Wnt5a, Axin2, and Lef1 mRNA levels of HMWTg joints compared to Vector. Values 
are the means ± SD. *P  <0.05**P <0.01, ***P  <0.001, n=7-8/group. 
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Figure 4.6.2. Basal characterization of primary immature murine articular chondrocytes 
cultured for 7 days. A, Alcian blue staining shows enhanced matrix proteoglycan production by 
HMWTg compared to Vector and LMWTg. Alkaline phosphatase staining was increased in 
HMWTg chondrocytes compared to Vector and LMWTg. The data is representative of 4 
independent experiments. Magnification = 4X. B, mRNA expression revealed modulated gene 
expression between genotypes by qPCR analysis. C, Phospho-GSK3 protein expression was 
significantly higher in HMWTg chondrocytes compared to Vector. The mRNA expression and 
protein levels were expressed as relative (fold changes) to the expression of the Vector group. 
Values are the means ± SD for 3 independent experiments. *:compared with Vector p< .05.  
#:compared with HMWTg p< .05.   
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Figure 4.6.3. Effect of IWR on primary articular chondrocytes from HMWTg, LMWTg, 
and Vector mice. A, Western blots showed increased Axin2 protein expression after treatment 
with IWR for 48 hours. Active -catenin protein expression was greatest in the HMWTg-Vehicle 
treated group and was decreased after IWR treatment in all genotypes. Statistical analysis of 
Western blots of Axin2/Actin and Active -catenin/Total -catenin from 3 independent 
experiments is represented as the means ± SD. B, Alcian blue staining showed a decrease in 
matrix proteoglycan production after IWR treatment in HMWTg chondrocytes compared to 
Vehicle-treated, while Vector and LMWTg IWR-treated cultures retained their Vehicle-treated 
phenotype. Following IWR treatment, alkaline phosphatase staining was decreased in HMWTg 
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with no effect on Vector and LMWTg chondrocytes. Magnification = 4X. C, IWR treatment 
modulated mRNA expression and rescued some gene expression in HMWTg cultures as 
indicated in the qPCR analysis. The mRNA expression is expressed as relative (fold changes) to 
the expression of the Vector group. Values are the means ± SD for 3 independent experiments. 
 p< .05.  ¢:compared with Vector + IWR p< .05. $:compared 
with HMWTg + Vehicle p< .05. #:compared with HMWTg + IWR p< .05.    
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Figure 4.6.4. Effect of FGF23Ab on joints of HMWTg and Vector female mice. A, Digital 
radiographs show flattening of the tibial plateau and joint space narrowing (bracket) in Vehicle-
treated HMWTg mice, while FGF23Ab-treated HMWTg knees have a similar phenotype to both 
Vector control groups. B, 3D reconstructive images show pitting and erosion of the surface 
(yellow arrows) in the HMWTg + Vehicle knees compared to the smooth contour of all other 
groups. High-resolution microCT sagittal images of HMWTg + Vehicle display flattened tibia 
(dashed arrow), thinning and abnormal morphology of subchondral bone (white arrow) and 
decreased trabecular number and thickness in the femoral and tibial epiphyses. HMWTg + 
Fgf23Ab phenotype resembles that of Vector + Vehicle and Vector + Fgf23Ab groups. C, 3D 
morphometric parameters revealed a significant decrease in BV/TV, Tb.N, and Tb.Th and 
increase in Tb.Sp in HMWTg + Vehicle femoral epiphyses compared with the Vector + Vehicle 
group, while there is some rescue in the HMWTg + FGF23Ab knees. BV/TV, trabecular bone 
volume; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Th; trabecular thickness. C, 
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qPCR analysis of mRNA taken from the knees shows increased expression of ColX, Mmp13, 
and Mmp9 in HMWTg + Vehicle mice, with some rescue in the HMWTg + FGF23Ab group. E, 
Safranin-O staining show decreased articular cartilage thickness (bracket) in HMWTg + Vehicle, 
which is restored in HMWTg + FGF23Ab. F-G, Representative immunohistochemical staining 
show increased MMP13 and MMP9 expression (arrows) in femoral articular cartilage of 
HMWTg + Vehicle, which is decreased in HMWTg + FGF23Ab. N=3-4/group. Values are the 
means ± SD.  p< .05.  ¢:compared with Vector + FGF23Ab 
p< .05. $:compared with HMWTg + Vehicle p< .05. #:compared with HMWTg + FGF23Ab p< 
.05.  
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Figure 4.6.5. Schematic model in which HMW FGF2-mediated FGF23 stimulation of 
chondrocyte differentiation and osteoarthritis is partially through modulation of the 
Wnt/β-catenin pathway. Overexpression of HMW FGF2 enhances FGF23 expression which 
results in enhanced Wnt7b and phospho-Lrp5 and reduced Sost and Dkk1 expression. Increased 
inactive phosphorylated Gsk3β and Axin2 allow β-catenin to accumulate and be translocated to 
the nucleus where it binds LEF/TCF promoting transcription of OA and chondrocyte 
hypertrophic genes. When HMW FGF2 is not overexpressed there is less FGF23 expression 
resulting in reduced Wnt7b and increased Sost and Dkk1 expression, ultimately leading to 
reduced Wnt/β-catenin signaling and less chondrocyte differentiation.  
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Table 4.6.1. Antibody Table 
Peptide/Prot
ein Target 
 
Name of 
Antibody 
Manufacturer/
Catalog 
Number 
Species Raised 
(Monoclonal/Polyclonal) 
Dilution 
SOST Mouse 
SOST/Sclerostin 
antibody 
 
R & D Systems, 
AF1589 
Goat;polyclonal 1:100 
LRP6 LRP6 (SER1490) 
polyclonal 
antibody 
  
Bioss, bs-3253R Rabbit;polyclonal 1:100 
LRP5 Anti-LRP5 
(phosphoT1492) 
antibody 
 
Abcam, 
ab203306 
 
Rabbit;polyclonal 1:100 
WNT5A Mouse/Rat Wnt-
5a antibody 
 
R & D Systems, 
AF645 
Goat;polyclonal 1:50 
WNT7B 
 
Wnt7b antibody 
 
GeneTex, 
GTX114881 
Rabbit;polyclonal 1:100 
GSK3β Anti-GSK3 beta 
(phospho Y216) 
antibody  
  
Abcam, 75745 Rabbit;polyclonal 1:50 
LEF1 
 
β-catenin  
 
 
MMP13 
 
MMP9 
Anti-LEF1 (AB1) 
antibody 
  
 
Non-phospho 
(Active) β-
Catenin 
(Ser33/37/Thr41) 
(D13A1) Rabbit 
mAb 
Anti-MMP13 
antibody 
 
  
MMP-9 antibody 
(C-20) 
Sigma-Aldrich, 
AV32404 
 
 
Cell Signaling, 
8814 
 
 
 
 
Abcam, 
ab39012 
 
 
Santa Cruz, 
sc6840 
Rabbit;polyclonal 
 
Rabbit;monoclonal 
 
 
Rabbit;polyconal 
 
Goat;polyclonal 
 
 
1:50 
 
1:50 
 
 
1:100 
 
1:100 
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  Table 4.6.2. Primers used in qRT-PCR. 
Gene Forward Reverse 
β-actin 
Axin2 
Sost 
Sostdc1 
Dkk1 
Wisp1 
Wnt5a 
Wnt7b 
Wnt16 
Wnt10b 
Lrp6 
Lef1 
5’-atggctggggtgttgaaggt-3’ 
5’-aacctatgcccgtttcctcta-3’ 
5’-ggaatgatgccacagaggtcat-3’ 
5’-actggatcggaggaggctatgg-3’ 
5’-gggagttctctatgagggcg-3’ 
5’-gtggacatccaactacacatcaa-3’ 
5’-ctccttcgcccaggttgttatag-3’ 
5’-ttctggaggaccgcatgaa-3’ 
5’-agtgcaggcaacatgaccg-3’ 
5’- ttctctcgggatttcttggattc-3’ 
5’-ggtgtcaaagaagcctctgc-3’ 
5’-gccaccgatgagatgatccc-3’ 
5’-atctggcaccacaccttctacaa-3’ 
5’-gagtgtaaagacttggtccacc-3’ 
5’-cccggttcatggtctggtt-3’ 
5’-tgtggctggactcgttgtgc-3’ 
5’-aagggtagggctggtagttg-3’ 
5’-aagttcgtggcctcctctg-3’ 
5’-tgtcttcgcaccttctccaatg-3’ 
5’-ggtccagcaagttttggtggta-3’ 
5’-ccacatgccgtactggacatc-3’ 
5’- tgcacttccgcttcaggttttc-3’ 
5’-acctcaatgcgatttgttcc-3’ 
5’-ttgatgtcggctaagtcgcc-3’ 
Mmp-13 
Mmp-9 
5’-ctttggcttagaggtgactgg-3’ 
5’-gcgtcgtgatccccacttac-3’ 
5’-aggcactccacatcttggttt-3’ 
5’-caggccgaataggagcgtc-3’ 
Adamts5 5’-cctgcccacccaatggtaaa-3’ 5’-ccacatagtagcctgtgccc-3’ 
Col10a1 
Col1a1 
5’-gggaccccaaggacctaaag-3’ 
5’-ggtcctcgtggtgctgct-3’ 
5’-gcccaactagacctatctcacct-3’ 
5’-acctttgcccccttctttg-3’ 
Fgf23 
Fgf18 
FGFR3 
FGFR3c 
5’-acttgtcgcagaagcatc-3’ 
5’-aaggagtgcgtgttcattgag-3’ 
5’-ccggctgacacttggtaag-3’ 
5’-gttctctctttgtagactgc-3’ 
5’-gtgggcgaacagtgtagaa-3’ 
5’-agcccacataccaaccagagt-3’ 
5’-cttgtcgatgccaatagcttct-3’ 
5’-agtacctggcagcacca-3’ 
IL-1β 
Ihh 
Sox9 
Nkx3.2 
5’-gcaactgttcctgaactcaact-3’ 
5’-ggcgctacgaaggcaagat-3’ 
5’-agtacccgcatctgcacaac-3’ 
5’-aaagtggccgtcaaggtgct-3’ 
5’-atcttttggggtccgtcaact-3’ 
 
5’-cttgaagatgatgtcgggattgt-3’ 
 
5’-acgaagggtctcttctcgct-3’ 
 
5’-agcccgggagacagtagtaa-3’ 
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Table 4.6.3. Relative fold change of gene expression of Vector, HMWTg, and 
LMWTg iMACs 
Gene Vector  HMWTg LMWTg Vector vs. 
HMWTg 
p-value 
Vector vs. 
LMWTg 
p-value 
HMWTg vs. 
LMWTg 
p-value 
Fgf18 1.02 ± 0.08 1.21 ± 0.19 1.94 ± 0.70 0.044 0.009 0.034 
FGFR3 0.97 ± 0.10 0.48 ± 0.21 1.35 ± 1.25 0.000 0.477 0.126 
FGFR3c 1.10 ± 0.13 1.48 ± 0.30 0.98 ± 1.00 0.017 0.766 0.263 
Mmp9 1.02 ± 0.10 2.57 ± 1.98 0.65 ± 0.43 0.086 0.067 0.043 
Sox9 
ColX 
Col1 
Ihh 
Nkx3.2 
Wnt10b 
Sostdc1 
Dkk1 
 
0.99 ± 0.08 
1.03 ± 0.05 
0.97 ± 0.11 
0.98 ± 0.04 
1.00 ± 0.04 
0.96 ± 0.18 
1.09 ± 0.24 
1.33 ± 0.37 
0.81 ± 0.21 
0.70 ± 0.40 
1.93 ± 0.52 
1.24 ± 1.07 
0.60 ± 0.12 
0.70 ± 0.17 
0.96 ± 0.64 
2.50 ± 1.26 
 
0.72 ± 0.27 
0.83 ± 0.22 
1.80 ± 0.77 
0.54 ± 0.26 
0.90 ± 0.21 
0.93 ± 0.34 
0.51 ± 0.26 
1.79 ± 0.32 
 
0.076 
0.071 
0.001 
0.571 
0.000 
0.030 
0.642 
0.056 
 
0.041 
0.049 
0.026 
0.002 
0.251 
0.885 
0.002 
0.044 
 
0.524 
0.502 
0.751 
0.150 
0.012 
0.160 
0.141 
0.216 
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Chapter 5 
Significance, Future Directions, and Conclusion 
5.1 Significance 
Though FGF2 has been well studied regarding its involvement in cartilage homeostasis 
and OA pathogenesis, and previous research suggests both a catabolic and anabolic role (25-28), 
the mechanism by which it causes these effects remained unknown. Firstly, we provide evidence 
that the two distinct isoforms of FGF2 play differing roles in OA and cartilage maintenance, an 
idea that had previously never been addressed. In doing so, we demonstrated that the contrasting 
effect of FGF2 on cartilage may be due to its isoforms, in that the high molecular weight isoform 
exerts a negative impact while the low molecular weight isoform is chondroprotective. 
Furthermore, FGF23 was known to be destructive in chondrocytes (45,46) and we were able to, 
for the first time, identify a potential mechanism by which this occurs, showing its regulation in 
Wnt/β signaling-mediated OA cartilage degradation. Concurrently, we add more evidence to the 
damaging potential of canonical Wnt signaling, rather than protective, as some former 
publications have reported (52). Additionally, it is of great importance that we were able to 
identify the articular chondrocyte as the component of the knee that is responsible for the 
pathogenesis of OA in our model, since various areas within an osteoarthritic joint can contribute 
to the disease. The chondrocyte in vitro studies recognized a possible pathway (canonical Wnt 
signaling) that could be targeted to prevent or inhibit OA initiation and prevention. Also, this 
study identified a potential therapeutic approach that partially rescued OA in vivo using a 
neutralizing FGF23Ab, a novel finding in that there are no disease modifying drugs to treat 
degenerative joint disease.  
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5.2 Future Directions 
 Although the current project revealed valuable information about FGF2 in the pathogeny 
of OA, future studies will still be needed to further clarify some of our results. While the 
mechanism by which HMW FGF2 negatively affects cartilage was determined, the biochemical 
pathway(s) involved in how the LMW FGF2 isoform positively regulates cartilage remains 
unknown. Our studies suggest that LMW FGF2 may enhances FGF18 and signal through 
FGFR3, which promotes an anabolic signaling cascade (27), but a more comprehensive analysis 
is needed. Also, this present work focused on articular chondrocytes and FGF2 should be studied 
in other cells types of the joint, including subchondral osteoblasts and osteoclasts or 
synoviocytes. Similarly, mouse models with tissue-specific deletions in cartilage or bone would 
be useful to delete full-length FGF2 or the selective isoform, since the knockout mouse models 
that were used had constitutive deletions. Even though it was determined that increased FGF23 
elevated Wnt7b levels, future studies are needed to understand how FGF23 regulates Wnt7b.  
 
5.3 Conclusion  
Broadly, the current research project demonstrated the following: (i) Mice overexpressing 
HMW FGF2 develop OA with an increase in FGF23 and FGFR1 in cartilage, while mice 
overexpressing LMW FGF2 do not develop OA. (ii) Neutralization of FGF23 attenuates some 
signs of OA in HMWTg. (iii) Mice only expressing HMW FGF2 and not LMW FGF2 develop 
OA similar to that observed in mice deficient in full-length FGF2, whereas mice expressing only 
LMW FGF2 are protected from age-related and mechanically-induced OA. (iv) Joints and 
chondrocytes of HMWTg have increased expression of components of canonical Wnt signaling 
leading to accelerated hypertrophy/differentiation, which is rescued by inhibiting Wnt. 
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 Specifically, HMW FGF2 modulates FGF23/FGFR1/Wnt/β-catenin signaling-mediated 
OA in chondrocytes. Overall, this work offers novel insight into the role of FGF2 in the 
pathophysiology of cartilage degradation in not only the context of XLH but overall OA disease, 
and specifies a candidate pathway to be targeted in the treatment or prevention of OA. 
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